<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02411539</url>
  </required_header>
  <id_info>
    <org_study_id>ACTG A5342</org_study_id>
    <secondary_id>12003</secondary_id>
    <secondary_id>UM1AI068636</secondary_id>
    <nct_id>NCT02411539</nct_id>
  </id_info>
  <brief_title>Evaluating the Safety, Tolerability, and Effect of a Human Monoclonal Antibody (VRC01) on Markers of HIV Persistence in HIV-Infected Adults Receiving Antiretroviral Therapy (ART)</brief_title>
  <official_title>A Phase I Study to Evaluate the Safety, Tolerability, and Effect of a Human Monoclonal Antibody, VRC-HIVMAB060-00-AB (VRC01), on Markers of HIV Persistence in ART-treated, HIV-infected Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AIDS Clinical Trials Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Vaccine Research Center at the National Institutes of Health (NIH)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study was to evaluate the safety, tolerability, and effect of an
      experimental human monoclonal antibody (mAb), VRC-HIVMAB060-00-AB (VRC01), in adults infected
      with HIV who were receiving antiretroviral therapy (ART).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Monoclonal antibodies (mAbs) have been developed as treatment for a variety of conditions
      including cancer, autoimmune disorders, and infections. mAbs may also be a potential
      treatment for people infected with HIV. The purpose of this study was to evaluate the safety
      and tolerability of an experimental human mAb, VRC-HIVMAB060-00-AB (VRC01), in HIV-infected
      adults receiving ART. Study researchers will also evaluate the effect of VRC01 on the number
      of infected cells containing unspliced HIV-1 transcripts in the blood in participants.

      This study enrolled HIV-infected people 18 to 65 years old, who had been receiving ART for at
      least 2 years and who had a CD4+ count of 200 cells/mm^3 or greater. Participants were
      randomly assigned to Arm A or Arm B. Participants in Arm A received an intravenous (IV)
      infusion of VRC01 at Day 0 and Week 3 and an IV infusion of placebo (normal saline) at Weeks
      6 and 9. Participants in Arm B received an IV infusion of placebo (normal saline) at Day 0
      and Week 3 and an IV infusion of VRC01 at Weeks 6 and 9. Participants recorded their
      temperature and symptoms for 3 days after each infusion. Study visits occured at study entry
      (Day 0), and Weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 15, 18, and 30. Study visits
      included physical examinations, clinical assessments, and blood collection.

      The primary safety outcome for this study was descriptive and assessed the occurrence of
      Grade â‰¥ 3 AEs including signs/symptoms, lab toxicities, and/or clinical events that are
      possibly, probably, or definitely related to study treatment (as judged by the core team,
      blinded to treatment arm) at any time from the initial dose of study treatment to the end of
      study follow-up. Since this outcome is descriptive, no statistical significance testing was
      performed.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 25, 2015</start_date>
  <completion_date type="Actual">September 29, 2016</completion_date>
  <primary_completion_date type="Actual">April 15, 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Who Experienced Grade 3 or Greater, Treatment Related, Adverse Event (AE)</measure>
    <time_frame>Measured from study treatment initiation to study discontinuation (study duration is 30 weeks)</time_frame>
    <description>Refer to detailed description in the protocol section.
Includes signs/symptoms, lab toxicities, and/or clinical events that are possibly, probably, or definitely related to study treatment (as judged by the core team, blinded to treatment arm) at any time from the initial dose of VRC01 to end of study follow-up. This analysis was primarily descriptive and no significance testing was performed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Cell-associated HIV-1 RNA/DNA Ratio in Total CD4+ Cells</measure>
    <time_frame>Screening, entry and week 6</time_frame>
    <description>Change from baseline (geometric average of screening and entry results) to week 6 in log10 transformed cell-associated HIV-1 RNA/DNA ratio in total CD4+ cells</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Premature Treatment Discontinuation, for Reasons Related to Study Treatment</measure>
    <time_frame>Measured from study treatment initiation to study treatment discontinuation (study treatment dispensed through week 12)</time_frame>
    <description>Study treatment was taken from entry through week 12 - this outcome assesses the number of participants who permanently and prematurely discontinued study treatment due to reasons related to the study treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Cell-associated HIV-1 RNA/DNA Ratio in Total CD4+ Cells - Last Value Carried Forward (LVCF)</measure>
    <time_frame>Screening, entry, week 3 and week 6 (week 3 used as LVCF if necessary)</time_frame>
    <description>Change from baseline (geometric average of screening and entry results) to week 6 in cell-associated HIV-1 RNA/DNA ratio in total CD4+ cells, using a last value carried forward approach if week 6 cell-associated HIV-1 RNA/DNA ratio was missing. In the event that the week 6 value was missing, the week 3 value was carried forward to be used. This comparison is the change from the average of screening and entry results to the week 6 value (if available), and if week 6 result was not available, the week 3 value was used instead of the week 6 value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Cell-associated HIV-1 RNA/DNA Ratio in Total CD4+ Cells - Across Arms</measure>
    <time_frame>Screening, entry and weeks 6 and 12</time_frame>
    <description>Summary of within-participant change across treatment arms from the pre-VRC01 time point to the post-VRC01 time point. For Arm A, the pre-VRC01 time point used was the baseline measure (geometric average of screening and entry results) and the post-VRC01 time point was the week 6 measure. For Arm B, the pre-VRC01 time point used was the week 6 measure and the post-VRC01 time point was the week 12 measure. Change in CA-RNA/DNA ratio was calculated on the log10 scale.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cell-associated HIV-1 RNA in Total CD4+ Cells</measure>
    <time_frame>Measured at screening, entry, weeks 1, 3, 4, 6, 7, 9, 10, 12, 15, 18 and 30</time_frame>
    <description>Testing priority was given to samples from screening, entry and weeks 3, 6, 9 and 12. Results from other time points will be available at a later time and will then be entered into CT.gov. Baseline values are the geometric mean of screening and entry results.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cell-associated HIV-1 DNA in Total CD4+ Cells</measure>
    <time_frame>Measured at screening, entry, weeks 1, 3, 4, 6, 7, 9, 10, 12, 15, 18 and 30</time_frame>
    <description>Testing priority was given to samples from screening, entry and weeks 3, 6, 9 and 12. Results from other time points will be available at a later time and will then be entered into CT.gov. Baseline values are the geometric mean of screening and entry results.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cell-associated HIV-1 RNA/DNA Ratio in Total CD4+ Cells</measure>
    <time_frame>Measured at screening, entry, weeks 1, 3, 4, 6, 7, 9, 10, 12, 15, 18 and 30</time_frame>
    <description>Testing priority was given to samples from screening, entry and weeks 3, 6, 9 and 12. Results from other time points will be available at a later time and will then be entered into CT.gov. Baseline values are the geometric mean of screening and entry results.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Plasma HIV-1 RNA by Single Copy Assay (SCA) Below Assay Lower Limit</measure>
    <time_frame>Measured at screening, entry and weeks 1, 3, 4, 6, 7, 9, 10, 12, 15, 18 and 30</time_frame>
    <description>The analysis of HIV-1 RNA SCA assessed the number of participants below the assay lower limit (1 copy/mL) at each measurement week. Specific specimens and time points were targeted based on Arm. Samples were not tested for Arm A at the Week 7 and Week 10 time points. Samples were not tested for Arm B at the Week 1 and Week 4 time points.
Testing of specimens at weeks 15, 18 and 30 has not been performed. The study team has decided in favor of saving these samples for future research purposes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CD4+ T-cell Counts</measure>
    <time_frame>Measured at screening, entry and weeks 6, 12, 18 and 30</time_frame>
    <description>Baseline measure represents the average of screening and entry results</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CD8+ T-cell Counts</measure>
    <time_frame>Measured at screening, entry and weeks 6, 12, 18 and 30</time_frame>
    <description>Baseline measure represents the average of screening and entry results</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total/Inducible Virus Recovery - Stimulated HIV-1 RNA</measure>
    <time_frame>Measured at pre-entry, week 6 and week 12</time_frame>
    <description>As part of the total virus recovery assay, results for stimulated HIV-1 RNA (copies/mL) are generated</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total/Inducible Virus Recovery - Unstimulated HIV-1 RNA</measure>
    <time_frame>Measured at pre-entry, week 6 and week 12</time_frame>
    <description>As part of the total virus recovery assay, results for unstimulated HIV-1 RNA (copies/mL) are generated</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total/Inducible Virus Recovery - Stimulated to Unstimulated HIV-1 RNA Ratio</measure>
    <time_frame>Measured at pre-entry, week 6 and week 12</time_frame>
    <description>As part of the total virus recovery assay, results for stimulated and unstimulated HIV-1 RNA (copies/mL) are generated. At each time point, the ratio of the stimulated to unstimulated HIV-1 RNA was calculated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total/Inducible Virus Recovery - Stimulated Cell Fluor</measure>
    <time_frame>Measured at pre-entry, week 6 and week 12</time_frame>
    <description>As part of the total virus recovery assay, results for stimulated cell fluor (light units) are generated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total/Inducible Virus Recovery - Unstimulated Cell Fluor</measure>
    <time_frame>Measured at pre-entry, week 6 and week 12</time_frame>
    <description>As part of the total virus recovery assay, results for unstimulated cell fluor (light units) are generated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total/Inducible Virus Recovery - Stimulated to Unstimulated Cell Fluor Ratio</measure>
    <time_frame>Measured at pre-entry, week 6 and week 12</time_frame>
    <description>As part of the total virus recovery assay, results for stimulated and unstimulated cell fluor (light units) are generated. At each time point, the ratio of the stimulated to unstimulated cell fluor was calculated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total/Inducible Virus Recovery - Percentage of Total CD4 Yield</measure>
    <time_frame>Measured at pre-entry, week 6 and week 12</time_frame>
    <description>As part of the total virus recovery assay, results for %tCD4 yield are generated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Total/Inducible Virus Recovery - Stimulated HIV-1 RNA</measure>
    <time_frame>Measured at pre-entry, week 6</time_frame>
    <description>As part of the total virus recovery assay, results for stimulated HIV-1 RNA (copies/mL) are generated. The change from the pre-treatment time point to week 6 was assessed as a fold change (week 6 / pre-entry)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Total/Inducible Virus Recovery - Unstimulated HIV-1 RNA</measure>
    <time_frame>Measured at pre-entry, week 6</time_frame>
    <description>As part of the total virus recovery assay, results for unstimulated HIV-1 RNA (copies/mL) are generated. The change from the pre-treatment time point to week 6 was assessed as a fold change (week 6 / pre-entry)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Total/Inducible Virus Recovery - Stimulated to Unstimulated HIV-1 RNA Ratio</measure>
    <time_frame>Measured at pre-entry and week 6</time_frame>
    <description>As part of the total virus recovery assay, results for stimulated and unstimulated HIV-1 RNA (copies/mL) are generated. At each time point, the ratio of the stimulated to unstimulated HIV-1 RNA was calculated. The fold change of this ratio from pre-entry to the week 6 time point was calculated for each arm (week 6 / pre-entry)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Total/Inducible Virus Recovery - Stimulated Cell Fluor</measure>
    <time_frame>Measured at pre-entry, week 6</time_frame>
    <description>As part of the total virus recovery assay, results for stimulated cell fluor (light units) are generated. The fold change from pre-entry to the week 6 time point was calculated for each arm (week 6 / pre-entry)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Total/Inducible Virus Recovery - Unstimulated Cell Fluor</measure>
    <time_frame>Measured at pre-entry, week 6</time_frame>
    <description>As part of the total virus recovery assay, results for unstimulated cell fluor (light units) are generated. The fold change from pre-entry to the week 6 time point was calculated for each arm (week 6 / pre-entry)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Total/Inducible Virus Recovery - Stimulated to Unstimulated Cell Fluor Ratio</measure>
    <time_frame>Measured at pre-entry, week 6</time_frame>
    <description>As part of the total virus recovery assay, results for stimulated and unstimulated cell fluor (light units) are generated. At each time point, the ratio of the stimulated to unstimulated cell fluor was calculated. The fold change of this ratio from pre-entry to the week 6 time point was calculated for each arm (week 6 / pre-entry)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Total/Inducible Virus Recovery - Percentage of Total CD4 Yield</measure>
    <time_frame>Measured at pre-entry, week 6</time_frame>
    <description>As part of the total virus recovery assay, results for %tCD4 yield are generated. The fold change from pre-entry to the week 6 time point was calculated for each arm (week 6 / pre-entry)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VRC01 Antibody Level</measure>
    <time_frame>Measured at entry and weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 15, 18 and 30</time_frame>
    <description>Summarize the pharmacokinetics (PK) of two infusions of VRC01 during study follow up
Specific specimens and time points were targeted for testing based on Arm. Samples for Arm A were not tested for the Week 6 and Week 9 post-infusion time points. Samples for Arm B were not tested for the Week 0 and Week 3 post-infusion time points.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Detectability of Antibody to VRC01 as Measured in Serum</measure>
    <time_frame>Measured at week 30</time_frame>
    <description>Assess the detectability of antibody to VRC01 in samples collected during study follow-up. Intended to be result from specimen at week 30 time point. Due to specimen availability, four participants in Arm A had results from specimens from the week 18 time point. Counts provided are number of participants with detectable anti-VRC01 antibody result.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Levels of T-cell Activation</measure>
    <time_frame>Measured at screening, entry and weeks 1, 3, 4, 6, 7, 9, 10, 12, 15, 18 and 30</time_frame>
    <description>% CD4+ and CD8+ T-cells co-expressing human leukocyte antigen (HLA)-DR and CD38
Not conducted as part of primary analysis and there are no future plans to assess this outcome. Samples were collected for this outcome in order to assess associations with virologic effects observed. Due to the lack of virologic effect observed, the study team has decided that this outcome is no longer of priority/interest and will be abandoned in favor of saving these samples for future research purposes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Levels of NK Cell Activation</measure>
    <time_frame>Measured at screening, entry and weeks 1, 3, 4, 6, 7, 9, 10, 12, 15, 18 and 30</time_frame>
    <description>% NK cells expressing CD69 or CD95
Not conducted as part of primary analysis and there are no future plans to assess this outcome. Samples were collected for this outcome in order to assess associations with virologic effects observed. Due to the lack of virologic effect observed, the study team has decided that this outcome is no longer of priority/interest and will be abandoned in favor of saving these samples for future research purposes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Levels of sCD163</measure>
    <time_frame>Measured at screening, entry and weeks 1, 3, 4, 6, 7, 9, 10, 12, 15, 18 and 30</time_frame>
    <description>Not conducted as part of primary analysis and there are no future plans to assess this outcome. Samples were collected for this outcome in order to assess associations with virologic effects observed. Due to the lack of virologic effect observed, the study team has decided that this outcome is no longer of priority/interest and will be abandoned in favor of saving these samples for future research purposes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Levels of sCD14</measure>
    <time_frame>Measured at screening, entry and weeks 1, 3, 4, 6, 7, 9, 10, 12, 15, 18 and 30</time_frame>
    <description>Not conducted as part of primary analysis and there are no future plans to assess this outcome. Samples were collected for this outcome in order to assess associations with virologic effects observed. Due to the lack of virologic effect observed, the study team has decided that this outcome is no longer of priority/interest and will be abandoned in favor of saving these samples for future research purposes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Levels of Interleukin-6 (IL-6)</measure>
    <time_frame>Measured at screening, entry and weeks 1, 3, 4, 6, 7, 9, 10, 12, 15, 18 and 30</time_frame>
    <description>Not conducted as part of primary analysis and there are no future plans to assess this outcome. Samples were collected for this outcome in order to assess associations with virologic effects observed. Due to the lack of virologic effect observed, the study team has decided that this outcome is no longer of priority/interest and will be abandoned in favor of saving these samples for future research purposes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Levels of Human Soluble Tumor Necrosis Factor Alpha-receptor (sTNFÎ±R)</measure>
    <time_frame>Measured at screening, entry and weeks 1, 3, 4, 6, 7, 9, 10, 12, 15, 18 and 30</time_frame>
    <description>Not conducted as part of primary analysis and there are no future plans to assess this outcome. Samples were collected for this outcome in order to assess associations with virologic effects observed. Due to the lack of virologic effect observed, the study team has decided that this outcome is no longer of priority/interest and will be abandoned in favor of saving these samples for future research purposes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Levels of Tumor Necrosis Factor Alpha (TNFÎ±)</measure>
    <time_frame>Measured at screening, entry and weeks 1, 3, 4, 6, 7, 9, 10, 12, 15, 18 and 30</time_frame>
    <description>Not conducted as part of primary analysis and there are no future plans to assess this outcome. Samples were collected for this outcome in order to assess associations with virologic effects observed. Due to the lack of virologic effect observed, the study team has decided that this outcome is no longer of priority/interest and will be abandoned in favor of saving these samples for future research purposes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Levels of High-sensitivity C-reactive Protein (hsCRP)</measure>
    <time_frame>Measured at screening, entry and weeks 1, 3, 4, 6, 7, 9, 10, 12, 15, 18 and 30</time_frame>
    <description>Not conducted as part of primary analysis and there are no future plans to assess this outcome. Samples were collected for this outcome in order to assess associations with virologic effects observed. Due to the lack of virologic effect observed, the study team has decided that this outcome is no longer of priority/interest and will be abandoned in favor of saving these samples for future research purposes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VRC01 Antibody Level Relative to Infusion Timing</measure>
    <time_frame>Measured immediately after first infusion (and 1, 2, and 3 weeks after), and immediately after second infusion (and 1, 2, 3, 6 and 9 weeks after)</time_frame>
    <description>Summarize the pharmacokinetics (PK) of two infusions of VRC01 during study follow up - aligning the timing of PK samples/results to the respective VRC01 infusions for each Arm</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>Arm A: VRC01 followed by placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received an infusion of VRC01 at Day 0 and Week 3 and an infusion of placebo (normal saline) at Weeks 6 and 9.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B: placebo followed by VRC01</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received an infusion of placebo (normal saline) at Day 0 and Week 3 and an infusion of VRC01 at Weeks 6 and 9.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>VRC01</intervention_name>
    <description>40 mg/kg of VRC01 administered as an intravenous infusion over about 30 to 60 minutes using a volumetric pump</description>
    <arm_group_label>Arm A: VRC01 followed by placebo</arm_group_label>
    <arm_group_label>Arm B: placebo followed by VRC01</arm_group_label>
    <other_name>VRC-HIVMAB060-00-AB</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Normal saline administered as an intravenous infusion over about 30 to 60 minutes using a volumetric pump</description>
    <arm_group_label>Arm A: VRC01 followed by placebo</arm_group_label>
    <arm_group_label>Arm B: placebo followed by VRC01</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HIV-1 infection, documented by any FDA-approved rapid HIV test or HIV enzyme or
             chemiluminescence immunoassay (E/CIA) test kit at any time prior to study entry and
             confirmed by a licensed Western blot or a second antibody test by a method other than
             the initial rapid HIV or E/CIA tests, or by HIV-1 antigen, or plasma HIV-1 RNA assay.
             More information on this criterion is available in the protocol.

          -  Received continuous ART for at least 2 years (defined as no interruptions longer than
             14 consecutive days) and with no changes in the components of the ART for at least 90
             days prior to study entry

          -  CD4+ cell count greater than or equal to 200 cells/mm^3 obtained within 60 days prior
             to study entry in a clinical laboratory improvement amendments (CLIA)-certified
             laboratory

          -  Plasma HIV-1 RNA below the limit of detection of the FDA-approved assays (limit of
             detection: 75, 50, 40 or 20 copies/mL) for greater than or equal to 2 years on ART.
             Participants must have had at least one documented HIV-1 RNA less than the limit of
             detection 12-24 months prior to study entry and at least one HIV-1 RNA less than the
             limit of detection within 12 months prior to study entry. All available HIV-1 RNA
             measurements must have been below the assay limit of detection during the 2 years
             prior to study entry except as allowed by the following note. NOTE: A single
             unconfirmed plasma HIV-1 RNA greater than the limit of detection but less than 200
             copies/mL within 6-24 months was allowed if followed by a subsequent value below the
             limit of detection.

          -  Plasma HIV-1 RNA level of less than 40 copies/mL obtained by the Abbott Real-time HIV
             assay (m2000) or less than 20 copies/mL obtained by the Roche COBAS Taqman HIV-1 v2.0
             assay within 60 days prior to entry

          -  The following laboratory values obtained within 60 days prior to entry by any U.S.
             laboratory that has a CLIA certification or its equivalent.

               -  Absolute neutrophil count (ANC) greater than or equal to 750 cells/mm^3

               -  Hemoglobin greater than or equal to 11.0 g/dL for men and greater than or equal
                  to 10.0 g/dL for women

               -  Platelet count greater than or equal to 100,000/mm^3

               -  Creatinine clearance greater than or equal to 60 mL/min estimated by the
                  Cockcroft-Gault equation. NOTE: A program for calculating creatinine clearance by
                  the Cockcroft-Gault method is available on www.fstrf.org.

               -  Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) (SGPT) less
                  than or equal to 2.0 times upper limit of normal (ULN)

          -  Hepatitis C virus (HCV) antibody negative result within 60 days prior to study entry
             or, if the HCV antibody result is positive, a negative HCV RNA result within 60 days
             prior to study entry

          -  Negative HBsAg result obtained within 60 days prior to study entry

          -  Ability and willingness of participant to provide informed consent

          -  Females of reproductive potential (women who have not been post-menopausal for at
             least 24 consecutive months, i.e., who have had menses within the preceding 24 months,
             or women who have not undergone surgical sterilization, specifically hysterectomy, or
             bilateral oophorectomy and/or bilateral salpingectomy), needed a negative serum or
             urine pregnancy test within 48 hours prior to study entry. NOTE: Acceptable
             documentation of hysterectomy and bilateral oophorectomy, bilateral salpingectomy,
             tubal micro-inserts, partner who has undergone vasectomy, and menopause is
             participant-reported history.

          -  All participants must have agreed not to participate in the conception process (e.g.,
             active attempt to become pregnant or to impregnate, sperm donation, in vitro
             fertilization), and if participating in sexual activity that could lead to pregnancy,
             the participant/partner must use at least one reliable form of contraception (condoms,
             with or without a spermicidal agent; a diaphragm or cervical cap with spermicide; an
             intrauterine device (IUD); or hormone-based contraceptive), while receiving study
             treatment and for 12 weeks after stopping study treatment

          -  Documentation of the availability of the following stored samples from the screening
             visit: peripheral blood mononuclear cell (PBMC) for CD4+ T-cell associated HIV-1 RNA,
             DNA assay and plasma for HIV-1 SCA. Sites must receive confirmation from the
             processing lab via phone, email, or fax, that specimens have been entered into the
             AIDS Clinical Trials Group (ACTG) Laboratory Data Management System (LDMS).

        Exclusion Criteria:

          -  Previous receipt of humanized or human monoclonal antibody (licensed or
             investigational)

          -  Weight greater than 115 kg or less than 53 kg

          -  Acute or ongoing AIDS-defining illness within 60 days prior to study entry

          -  History of a severe allergic reaction with generalized urticarial, angioedema, or
             anaphylaxis within 2 years of study entry

          -  Currently breastfeeding or pregnant

          -  Active drug or alcohol use or dependence that, in the opinion of the site
             investigator, would interfere with adherence to study requirements

          -  Acute or serious illness that, in the opinion of the site investigator, requires
             systemic treatment and/or hospitalization within 60 days prior to entry

          -  Use of immunomodulators (e.g., interleukins, interferons, cyclosporine), HIV vaccine,
             systemic cytotoxic chemotherapy, or investigational therapy within 60 days prior to
             study entry. NOTE: Participants receiving stable physiologic doses of glucocorticoids,
             defined as the equivalent of prednisone less than or equal to 10 mg/day, will not be
             excluded. Stable physiologic glucocorticoid doses should not be discontinued for the
             duration of the study. In addition, participants receiving inhaled or topical
             corticosteroids will not be excluded.

          -  Treatment for hepatitis C within 24 weeks of study entry

          -  Vaccinations within 7 days prior to the screening, pre-entry, or study entry visits.
             NOTE: Participants are encouraged to get routine vaccinations, such as seasonal
             influenza vaccine more than 7 days prior to screening or between screening and
             pre-entry visits (outside of the 7-day window above).

          -  Initiation of ART during acute HIV-1 infection (as determined by the site investigator
             by history and/or available medical records)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sharon Riddler, MD, MPH</last_name>
    <role>Study Chair</role>
    <affiliation>Pitt CRS</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCSD Antiviral Research Center CRS</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado Hospital CRS</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern University CRS</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University CRS</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital CRS (MGH CRS)</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University Therapeutics (WT) CRS</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110-1010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Rochester Adult HIV Therapeutic Strategies Network CRS</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chapel Hill CRS</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohio State University CRS</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh CRS</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt Therapeutics (VT) CRS</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Houston AIDS Research Team CRS</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Washington AIDS CRS</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104-9929</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Puerto Rico</country>
  </removed_countries>
  <link>
    <url>http://rsc.tech-res.com/safetyandpharmacovigilance/</url>
    <description>To grade diagnoses, signs and symptoms, and laboratory results, sites referred to the DAIDS Table for Grading the Severity of Adult and Pediatric Adverse Events (DAIDS AE Grading Table), Version 2.0, November 2014</description>
  </link>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 2, 2015</study_first_submitted>
  <study_first_submitted_qc>April 6, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 8, 2015</study_first_posted>
  <results_first_submitted>March 17, 2017</results_first_submitted>
  <results_first_submitted_qc>May 3, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">July 31, 2017</results_first_posted>
  <last_update_submitted>February 27, 2018</last_update_submitted>
  <last_update_submitted_qc>February 27, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 27, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>VRC01</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The first participant enrolled to the study on August 25th, 2015 and the last participant enrolled on March 4th, 2016. A total of 13 U.S. sites enrolled participants.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Arm A: VRC01 Followed by Placebo</title>
          <description>Participants received an infusion of VRC01 at Day 0 and Week 3 and an infusion of placebo at Weeks 6 and 9.
VRC01: 40 mg/kg of VRC01 administered as an intravenous infusion over about 30 to 60 minutes using a volumetric pump
Placebo: Normal saline administered as an intravenous infusion over about 30 to 60 minutes using a volumetric pump</description>
        </group>
        <group group_id="P2">
          <title>Arm B: Placebo Followed by VRC01</title>
          <description>Participants received an infusion of placebo at Day 0 and Week 3 and an infusion of VRC01 at Weeks 6 and 9.
VRC01: 40 mg/kg of VRC01 administered as an intravenous infusion over about 30 to 60 minutes using a volumetric pump
Placebo: Normal saline administered as an intravenous infusion over about 30 to 60 minutes using a volumetric pump</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Confounding medical condition</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All participants enrolled</population>
      <group_list>
        <group group_id="B1">
          <title>Arm A: VRC01 Followed by Placebo</title>
          <description>Participants received an infusion of VRC01 at Day 0 and Week 3 and an infusion of placebo at Weeks 6 and 9.
VRC01: 40 mg/kg of VRC01 administered as an intravenous infusion over about 30 to 60 minutes using a volumetric pump
Placebo: Normal saline administered as an intravenous infusion over about 30 to 60 minutes using a volumetric pump</description>
        </group>
        <group group_id="B2">
          <title>Arm B: Placebo Followed by VRC01</title>
          <description>Participants received an infusion of placebo at Day 0 and Week 3 and an infusion of VRC01 at Weeks 6 and 9.
VRC01: 40 mg/kg of VRC01 administered as an intravenous infusion over about 30 to 60 minutes using a volumetric pump
Placebo: Normal saline administered as an intravenous infusion over about 30 to 60 minutes using a volumetric pump</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
            <count group_id="B2" value="20"/>
            <count group_id="B3" value="40"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="20"/>
                    <count group_id="B2" value="20"/>
                    <count group_id="B3" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44" spread="12"/>
                    <measurement group_id="B2" value="52" spread="11"/>
                    <measurement group_id="B3" value="48" spread="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <description>Age at enrollment, categorized</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>18-29 years</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="20"/>
                    <count group_id="B2" value="20"/>
                    <count group_id="B3" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30-39 years</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="20"/>
                    <count group_id="B2" value="20"/>
                    <count group_id="B3" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>40-49 years</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="20"/>
                    <count group_id="B2" value="20"/>
                    <count group_id="B3" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>50+ years</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="20"/>
                    <count group_id="B2" value="20"/>
                    <count group_id="B3" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="20"/>
                    <count group_id="B2" value="20"/>
                    <count group_id="B3" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>White non-hispanic</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="20"/>
                    <count group_id="B2" value="20"/>
                    <count group_id="B3" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black non-hispanic</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="20"/>
                    <count group_id="B2" value="20"/>
                    <count group_id="B3" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic (regardless of race)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="20"/>
                    <count group_id="B2" value="20"/>
                    <count group_id="B3" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>IV drug history, categorical</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Never</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="20"/>
                    <count group_id="B2" value="20"/>
                    <count group_id="B3" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Previously</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="20"/>
                    <count group_id="B2" value="20"/>
                    <count group_id="B3" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI, categorical</title>
          <description>Categories from entry visit</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Underweight (&lt;18 kg/m^2)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="20"/>
                    <count group_id="B2" value="20"/>
                    <count group_id="B3" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Normal (18 - &lt;25 kg/m^2)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="20"/>
                    <count group_id="B2" value="20"/>
                    <count group_id="B3" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Overweight (25 - &lt;30 kg/m^2)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="20"/>
                    <count group_id="B2" value="20"/>
                    <count group_id="B3" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Obese (30+ kg/m^2)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="20"/>
                    <count group_id="B2" value="20"/>
                    <count group_id="B3" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Plasma HIV-1 RNA, categorical</title>
          <description>Categorization of the result from the entry visit</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>&lt; 40 copies/mL</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="20"/>
                    <count group_id="B2" value="20"/>
                    <count group_id="B3" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;= 40 copies/mL</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="20"/>
                    <count group_id="B2" value="20"/>
                    <count group_id="B3" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>CD4+ T-Cell Count, categorical</title>
          <description>Categorization of the average results from the screening and entry visits</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>200 - &lt;350 cells/mm^3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="20"/>
                    <count group_id="B2" value="20"/>
                    <count group_id="B3" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>350 - &lt;500 cells/mm^3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="20"/>
                    <count group_id="B2" value="20"/>
                    <count group_id="B3" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;= 500 cells/mm^3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="20"/>
                    <count group_id="B2" value="20"/>
                    <count group_id="B3" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Creatinine clearance, categorical</title>
          <description>Categorization of the average results from the screening and entry visits</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>50 - 90 mL/min</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="20"/>
                    <count group_id="B2" value="20"/>
                    <count group_id="B3" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt; 90 mL/min</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="20"/>
                    <count group_id="B2" value="20"/>
                    <count group_id="B3" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Cell-associated HIV-1 RNA/DNA Ratio</title>
          <population>Geometric average of screening and entry results. Results were not available for two participants</population>
          <units>log10 ratio</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="19"/>
                    <count group_id="B2" value="19"/>
                    <count group_id="B3" value="38"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="-1.35" lower_limit="-1.63" upper_limit="-1.02"/>
                    <measurement group_id="B2" value="-1.51" lower_limit="-1.69" upper_limit="-1.30"/>
                    <measurement group_id="B3" value="-1.45" lower_limit="-1.63" upper_limit="-1.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Who Experienced Grade 3 or Greater, Treatment Related, Adverse Event (AE)</title>
        <description>Refer to detailed description in the protocol section.
Includes signs/symptoms, lab toxicities, and/or clinical events that are possibly, probably, or definitely related to study treatment (as judged by the core team, blinded to treatment arm) at any time from the initial dose of VRC01 to end of study follow-up. This analysis was primarily descriptive and no significance testing was performed.</description>
        <time_frame>Measured from study treatment initiation to study discontinuation (study duration is 30 weeks)</time_frame>
        <population>Includes all available follow-up for all participants</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A: VRC01 Followed by Placebo</title>
            <description>Participants received an infusion of VRC01 at Day 0 and Week 3 and an infusion of placebo at Weeks 6 and 9.
VRC01: 40 mg/kg of VRC01 administered as an intravenous infusion over about 30 to 60 minutes using a volumetric pump
Placebo: Normal saline administered as an intravenous infusion over about 30 to 60 minutes using a volumetric pump</description>
          </group>
          <group group_id="O2">
            <title>Arm B: Placebo Followed by VRC01</title>
            <description>Participants received an infusion of placebo at Day 0 and Week 3 and an infusion of VRC01 at Weeks 6 and 9.
VRC01: 40 mg/kg of VRC01 administered as an intravenous infusion over about 30 to 60 minutes using a volumetric pump
Placebo: Normal saline administered as an intravenous infusion over about 30 to 60 minutes using a volumetric pump</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Experienced Grade 3 or Greater, Treatment Related, Adverse Event (AE)</title>
          <description>Refer to detailed description in the protocol section.
Includes signs/symptoms, lab toxicities, and/or clinical events that are possibly, probably, or definitely related to study treatment (as judged by the core team, blinded to treatment arm) at any time from the initial dose of VRC01 to end of study follow-up. This analysis was primarily descriptive and no significance testing was performed.</description>
          <population>Includes all available follow-up for all participants</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Cell-associated HIV-1 RNA/DNA Ratio in Total CD4+ Cells</title>
        <description>Change from baseline (geometric average of screening and entry results) to week 6 in log10 transformed cell-associated HIV-1 RNA/DNA ratio in total CD4+ cells</description>
        <time_frame>Screening, entry and week 6</time_frame>
        <population>Analysis of participants with available results for the change in cell-associated HIV-1 RNA/DNA ratio in total CD4+ cells. All participants received at least one dose of the randomized treatment assigned. No participants received the incorrect treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A: VRC01 Followed by Placebo</title>
            <description>Participants received an infusion of VRC01 at Day 0 and Week 3 and an infusion of placebo at Weeks 6 and 9.
VRC01: 40 mg/kg of VRC01 administered as an intravenous infusion over about 30 to 60 minutes using a volumetric pump
Placebo: Normal saline administered as an intravenous infusion over about 30 to 60 minutes using a volumetric pump</description>
          </group>
          <group group_id="O2">
            <title>Arm B: Placebo Followed by VRC01</title>
            <description>Participants received an infusion of placebo at Day 0 and Week 3 and an infusion of VRC01 at Weeks 6 and 9.
VRC01: 40 mg/kg of VRC01 administered as an intravenous infusion over about 30 to 60 minutes using a volumetric pump
Placebo: Normal saline administered as an intravenous infusion over about 30 to 60 minutes using a volumetric pump</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Cell-associated HIV-1 RNA/DNA Ratio in Total CD4+ Cells</title>
          <description>Change from baseline (geometric average of screening and entry results) to week 6 in log10 transformed cell-associated HIV-1 RNA/DNA ratio in total CD4+ cells</description>
          <population>Analysis of participants with available results for the change in cell-associated HIV-1 RNA/DNA ratio in total CD4+ cells. All participants received at least one dose of the randomized treatment assigned. No participants received the incorrect treatment.</population>
          <units>log10 ratio</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.05" lower_limit="-0.03" upper_limit="0.33"/>
                    <measurement group_id="O2" value="-0.08" lower_limit="-0.24" upper_limit="0.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The primary efficacy analysis compared the change in cell-associated HIV-1 RNA/DNA ratio (log-transformed) from baseline to week 6 between the two randomized arms, testing the null hypothesis of no difference in changes in cell-associated HIV-1 RNA/DNA ratio between the two arms using a Wilcoxon rank sum test at 10% significance level.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Assuming that a common standard deviation of change (measured as difference of log10 transformed HIV-1 RNA/DNA ratios) in both arms was 0.30, with a sample size of 36 evaluable participants (18 in each arm), the study had 88% power to detect an effect size of 0.30 log10 (2-fold) in change of cell-associated HIV-1 RNA/DNA from baseline to week 6 using a two-sided Wilcoxon rank sum test at 10% type I error rate assuming a normal distribution</non_inferiority_desc>
            <p_value>0.16</p_value>
            <p_value_desc>Two-sided Wilcoxon rank sum test at 10% significance level. Not adjusted for multiple comparisons.</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Premature Treatment Discontinuation, for Reasons Related to Study Treatment</title>
        <description>Study treatment was taken from entry through week 12 - this outcome assesses the number of participants who permanently and prematurely discontinued study treatment due to reasons related to the study treatment</description>
        <time_frame>Measured from study treatment initiation to study treatment discontinuation (study treatment dispensed through week 12)</time_frame>
        <population>All participants who received at least one infusion of study treatment</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A: VRC01 Followed by Placebo</title>
            <description>Participants received an infusion of VRC01 at Day 0 and Week 3 and an infusion of placebo at Weeks 6 and 9.
VRC01: 40 mg/kg of VRC01 administered as an intravenous infusion over about 30 to 60 minutes using a volumetric pump
Placebo: Normal saline administered as an intravenous infusion over about 30 to 60 minutes using a volumetric pump</description>
          </group>
          <group group_id="O2">
            <title>Arm B: Placebo Followed by VRC01</title>
            <description>Participants received an infusion of placebo at Day 0 and Week 3 and an infusion of VRC01 at Weeks 6 and 9.
VRC01: 40 mg/kg of VRC01 administered as an intravenous infusion over about 30 to 60 minutes using a volumetric pump
Placebo: Normal saline administered as an intravenous infusion over about 30 to 60 minutes using a volumetric pump</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Premature Treatment Discontinuation, for Reasons Related to Study Treatment</title>
          <description>Study treatment was taken from entry through week 12 - this outcome assesses the number of participants who permanently and prematurely discontinued study treatment due to reasons related to the study treatment</description>
          <population>All participants who received at least one infusion of study treatment</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Cell-associated HIV-1 RNA/DNA Ratio in Total CD4+ Cells - Last Value Carried Forward (LVCF)</title>
        <description>Change from baseline (geometric average of screening and entry results) to week 6 in cell-associated HIV-1 RNA/DNA ratio in total CD4+ cells, using a last value carried forward approach if week 6 cell-associated HIV-1 RNA/DNA ratio was missing. In the event that the week 6 value was missing, the week 3 value was carried forward to be used. This comparison is the change from the average of screening and entry results to the week 6 value (if available), and if week 6 result was not available, the week 3 value was used instead of the week 6 value.</description>
        <time_frame>Screening, entry, week 3 and week 6 (week 3 used as LVCF if necessary)</time_frame>
        <population>Analysis of participants with available results for the change in cell-associated HIV-1 RNA/DNA ratio in total CD4+ cells, carrying last available result forward if missing at week 6</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A: VRC01 Followed by Placebo</title>
            <description>Participants received an infusion of VRC01 at Day 0 and Week 3 and an infusion of placebo at Weeks 6 and 9.
VRC01: 40 mg/kg of VRC01 administered as an intravenous infusion over about 30 to 60 minutes using a volumetric pump
Placebo: Normal saline administered as an intravenous infusion over about 30 to 60 minutes using a volumetric pump</description>
          </group>
          <group group_id="O2">
            <title>Arm B: Placebo Followed by VRC01</title>
            <description>Participants received an infusion of placebo at Day 0 and Week 3 and an infusion of VRC01 at Weeks 6 and 9.
VRC01: 40 mg/kg of VRC01 administered as an intravenous infusion over about 30 to 60 minutes using a volumetric pump
Placebo: Normal saline administered as an intravenous infusion over about 30 to 60 minutes using a volumetric pump</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Cell-associated HIV-1 RNA/DNA Ratio in Total CD4+ Cells - Last Value Carried Forward (LVCF)</title>
          <description>Change from baseline (geometric average of screening and entry results) to week 6 in cell-associated HIV-1 RNA/DNA ratio in total CD4+ cells, using a last value carried forward approach if week 6 cell-associated HIV-1 RNA/DNA ratio was missing. In the event that the week 6 value was missing, the week 3 value was carried forward to be used. This comparison is the change from the average of screening and entry results to the week 6 value (if available), and if week 6 result was not available, the week 3 value was used instead of the week 6 value.</description>
          <population>Analysis of participants with available results for the change in cell-associated HIV-1 RNA/DNA ratio in total CD4+ cells, carrying last available result forward if missing at week 6</population>
          <units>log10 ratio</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.06" lower_limit="-0.03" upper_limit="0.53"/>
                    <measurement group_id="O2" value="-0.08" lower_limit="-0.24" upper_limit="0.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Cell-associated HIV-1 RNA/DNA Ratio in Total CD4+ Cells - Across Arms</title>
        <description>Summary of within-participant change across treatment arms from the pre-VRC01 time point to the post-VRC01 time point. For Arm A, the pre-VRC01 time point used was the baseline measure (geometric average of screening and entry results) and the post-VRC01 time point was the week 6 measure. For Arm B, the pre-VRC01 time point used was the week 6 measure and the post-VRC01 time point was the week 12 measure. Change in CA-RNA/DNA ratio was calculated on the log10 scale.</description>
        <time_frame>Screening, entry and weeks 6 and 12</time_frame>
        <population>Analysis of all participants with available pre- and post-VRC01 cell-associated RNA/DNA ratio results available. Participants from Arm A must have had results at entry and week 6. Participants from Arm B must have had results from week 6 and week 12.</population>
        <group_list>
          <group group_id="O1">
            <title>Across Arms</title>
            <description>Compare the pre-VRC01 and post-VRC01 time points across randomized Arms A/B. Arm A participants received an infusion of VRC01 at Day 0 and Week 3 and an infusion of placebo at Weeks 6 and 9. Arm B participants received an infusion of placebo at Day 0 and Week 3 and an infusion of VRC01 at Weeks 6 and 9. This group is to identify analyses that were assessed across randomized arms between the pre- and post-VRC01 time points.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Cell-associated HIV-1 RNA/DNA Ratio in Total CD4+ Cells - Across Arms</title>
          <description>Summary of within-participant change across treatment arms from the pre-VRC01 time point to the post-VRC01 time point. For Arm A, the pre-VRC01 time point used was the baseline measure (geometric average of screening and entry results) and the post-VRC01 time point was the week 6 measure. For Arm B, the pre-VRC01 time point used was the week 6 measure and the post-VRC01 time point was the week 12 measure. Change in CA-RNA/DNA ratio was calculated on the log10 scale.</description>
          <population>Analysis of all participants with available pre- and post-VRC01 cell-associated RNA/DNA ratio results available. Participants from Arm A must have had results at entry and week 6. Participants from Arm B must have had results from week 6 and week 12.</population>
          <units>log10 ratio</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.09" lower_limit="-0.22" upper_limit="0.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cell-associated HIV-1 RNA in Total CD4+ Cells</title>
        <description>Testing priority was given to samples from screening, entry and weeks 3, 6, 9 and 12. Results from other time points will be available at a later time and will then be entered into CT.gov. Baseline values are the geometric mean of screening and entry results.</description>
        <time_frame>Measured at screening, entry, weeks 1, 3, 4, 6, 7, 9, 10, 12, 15, 18 and 30</time_frame>
        <population>Analysis of participants with available cell-associated HIV-1 RNA results</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A: VRC01 Followed by Placebo</title>
            <description>Participants received an infusion of VRC01 at Day 0 and Week 3 and an infusion of placebo at Weeks 6 and 9.
VRC01: 40 mg/kg of VRC01 administered as an intravenous infusion over about 30 to 60 minutes using a volumetric pump
Placebo: Normal saline administered as an intravenous infusion over about 30 to 60 minutes using a volumetric pump</description>
          </group>
          <group group_id="O2">
            <title>Arm B: Placebo Followed by VRC01</title>
            <description>Participants received an infusion of placebo at Day 0 and Week 3 and an infusion of VRC01 at Weeks 6 and 9.
VRC01: 40 mg/kg of VRC01 administered as an intravenous infusion over about 30 to 60 minutes using a volumetric pump
Placebo: Normal saline administered as an intravenous infusion over about 30 to 60 minutes using a volumetric pump</description>
          </group>
        </group_list>
        <measure>
          <title>Cell-associated HIV-1 RNA in Total CD4+ Cells</title>
          <description>Testing priority was given to samples from screening, entry and weeks 3, 6, 9 and 12. Results from other time points will be available at a later time and will then be entered into CT.gov. Baseline values are the geometric mean of screening and entry results.</description>
          <population>Analysis of participants with available cell-associated HIV-1 RNA results</population>
          <units>log10 copies/million CD4</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.60" lower_limit="0.90" upper_limit="2.09"/>
                    <measurement group_id="O2" value="1.38" lower_limit="0.90" upper_limit="2.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.62" lower_limit="0.87" upper_limit="2.09"/>
                    <measurement group_id="O2" value="1.56" lower_limit="0.71" upper_limit="1.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.48" lower_limit="1.11" upper_limit="2.10"/>
                    <measurement group_id="O2" value="1.41" lower_limit="0.99" upper_limit="1.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 9</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.56" lower_limit="1.14" upper_limit="1.90"/>
                    <measurement group_id="O2" value="1.56" lower_limit="0.74" upper_limit="1.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.62" lower_limit="0.73" upper_limit="2.03"/>
                    <measurement group_id="O2" value="1.51" lower_limit="0.76" upper_limit="2.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cell-associated HIV-1 DNA in Total CD4+ Cells</title>
        <description>Testing priority was given to samples from screening, entry and weeks 3, 6, 9 and 12. Results from other time points will be available at a later time and will then be entered into CT.gov. Baseline values are the geometric mean of screening and entry results.</description>
        <time_frame>Measured at screening, entry, weeks 1, 3, 4, 6, 7, 9, 10, 12, 15, 18 and 30</time_frame>
        <population>Analysis of participants with available cell-associated HIV-1 DNA results</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A: VRC01 Followed by Placebo</title>
            <description>Participants received an infusion of VRC01 at Day 0 and Week 3 and an infusion of placebo at Weeks 6 and 9.
VRC01: 40 mg/kg of VRC01 administered as an intravenous infusion over about 30 to 60 minutes using a volumetric pump
Placebo: Normal saline administered as an intravenous infusion over about 30 to 60 minutes using a volumetric pump</description>
          </group>
          <group group_id="O2">
            <title>Arm B: Placebo Followed by VRC01</title>
            <description>Participants received an infusion of placebo at Day 0 and Week 3 and an infusion of VRC01 at Weeks 6 and 9.
VRC01: 40 mg/kg of VRC01 administered as an intravenous infusion over about 30 to 60 minutes using a volumetric pump
Placebo: Normal saline administered as an intravenous infusion over about 30 to 60 minutes using a volumetric pump</description>
          </group>
        </group_list>
        <measure>
          <title>Cell-associated HIV-1 DNA in Total CD4+ Cells</title>
          <description>Testing priority was given to samples from screening, entry and weeks 3, 6, 9 and 12. Results from other time points will be available at a later time and will then be entered into CT.gov. Baseline values are the geometric mean of screening and entry results.</description>
          <population>Analysis of participants with available cell-associated HIV-1 DNA results</population>
          <units>log10 copies/million CD4</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.05" lower_limit="2.42" upper_limit="3.20"/>
                    <measurement group_id="O2" value="3.00" lower_limit="2.53" upper_limit="3.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.99" lower_limit="2.50" upper_limit="3.15"/>
                    <measurement group_id="O2" value="2.89" lower_limit="2.61" upper_limit="3.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.99" lower_limit="2.46" upper_limit="3.07"/>
                    <measurement group_id="O2" value="2.92" lower_limit="2.54" upper_limit="3.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 9</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.96" lower_limit="2.46" upper_limit="3.23"/>
                    <measurement group_id="O2" value="2.91" lower_limit="2.57" upper_limit="3.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.01" lower_limit="2.70" upper_limit="3.17"/>
                    <measurement group_id="O2" value="2.90" lower_limit="2.55" upper_limit="3.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cell-associated HIV-1 RNA/DNA Ratio in Total CD4+ Cells</title>
        <description>Testing priority was given to samples from screening, entry and weeks 3, 6, 9 and 12. Results from other time points will be available at a later time and will then be entered into CT.gov. Baseline values are the geometric mean of screening and entry results.</description>
        <time_frame>Measured at screening, entry, weeks 1, 3, 4, 6, 7, 9, 10, 12, 15, 18 and 30</time_frame>
        <population>Analysis of participants with available cell-associated HIV-1 RNA/DNA ratio</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A: VRC01 Followed by Placebo</title>
            <description>Participants received an infusion of VRC01 at Day 0 and Week 3 and an infusion of placebo at Weeks 6 and 9.
VRC01: 40 mg/kg of VRC01 administered as an intravenous infusion over about 30 to 60 minutes using a volumetric pump
Placebo: Normal saline administered as an intravenous infusion over about 30 to 60 minutes using a volumetric pump</description>
          </group>
          <group group_id="O2">
            <title>Arm B: Placebo Followed by VRC01</title>
            <description>Participants received an infusion of placebo at Day 0 and Week 3 and an infusion of VRC01 at Weeks 6 and 9.
VRC01: 40 mg/kg of VRC01 administered as an intravenous infusion over about 30 to 60 minutes using a volumetric pump
Placebo: Normal saline administered as an intravenous infusion over about 30 to 60 minutes using a volumetric pump</description>
          </group>
        </group_list>
        <measure>
          <title>Cell-associated HIV-1 RNA/DNA Ratio in Total CD4+ Cells</title>
          <description>Testing priority was given to samples from screening, entry and weeks 3, 6, 9 and 12. Results from other time points will be available at a later time and will then be entered into CT.gov. Baseline values are the geometric mean of screening and entry results.</description>
          <population>Analysis of participants with available cell-associated HIV-1 RNA/DNA ratio</population>
          <units>log10 ratio</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.35" lower_limit="-1.63" upper_limit="-1.02"/>
                    <measurement group_id="O2" value="-1.51" lower_limit="-1.69" upper_limit="-1.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.29" lower_limit="-1.84" upper_limit="-0.74"/>
                    <measurement group_id="O2" value="-1.38" lower_limit="-1.57" upper_limit="-1.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.28" lower_limit="-1.54" upper_limit="-0.88"/>
                    <measurement group_id="O2" value="-1.44" lower_limit="-1.78" upper_limit="-1.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 9</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.37" lower_limit="-1.55" upper_limit="-1.06"/>
                    <measurement group_id="O2" value="-1.40" lower_limit="-1.80" upper_limit="-1.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.42" lower_limit="-1.80" upper_limit="-1.04"/>
                    <measurement group_id="O2" value="-1.33" lower_limit="-1.87" upper_limit="-1.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Plasma HIV-1 RNA by Single Copy Assay (SCA) Below Assay Lower Limit</title>
        <description>The analysis of HIV-1 RNA SCA assessed the number of participants below the assay lower limit (1 copy/mL) at each measurement week. Specific specimens and time points were targeted based on Arm. Samples were not tested for Arm A at the Week 7 and Week 10 time points. Samples were not tested for Arm B at the Week 1 and Week 4 time points.
Testing of specimens at weeks 15, 18 and 30 has not been performed. The study team has decided in favor of saving these samples for future research purposes.</description>
        <time_frame>Measured at screening, entry and weeks 1, 3, 4, 6, 7, 9, 10, 12, 15, 18 and 30</time_frame>
        <population>Analysis of participants with available SCA results</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A: VRC01 Followed by Placebo</title>
            <description>Participants received an infusion of VRC01 at Day 0 and Week 3 and an infusion of placebo at Weeks 6 and 9.
VRC01: 40 mg/kg of VRC01 administered as an intravenous infusion over about 30 to 60 minutes using a volumetric pump
Placebo: Normal saline administered as an intravenous infusion over about 30 to 60 minutes using a volumetric pump</description>
          </group>
          <group group_id="O2">
            <title>Arm B: Placebo Followed by VRC01</title>
            <description>Participants received an infusion of placebo at Day 0 and Week 3 and an infusion of VRC01 at Weeks 6 and 9.
VRC01: 40 mg/kg of VRC01 administered as an intravenous infusion over about 30 to 60 minutes using a volumetric pump
Placebo: Normal saline administered as an intravenous infusion over about 30 to 60 minutes using a volumetric pump</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Plasma HIV-1 RNA by Single Copy Assay (SCA) Below Assay Lower Limit</title>
          <description>The analysis of HIV-1 RNA SCA assessed the number of participants below the assay lower limit (1 copy/mL) at each measurement week. Specific specimens and time points were targeted based on Arm. Samples were not tested for Arm A at the Week 7 and Week 10 time points. Samples were not tested for Arm B at the Week 1 and Week 4 time points.
Testing of specimens at weeks 15, 18 and 30 has not been performed. The study team has decided in favor of saving these samples for future research purposes.</description>
          <population>Analysis of participants with available SCA results</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Screening</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Entry</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 9</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 10</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CD4+ T-cell Counts</title>
        <description>Baseline measure represents the average of screening and entry results</description>
        <time_frame>Measured at screening, entry and weeks 6, 12, 18 and 30</time_frame>
        <population>Analysis of all participants with available CD4+ results</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A: VRC01 Followed by Placebo</title>
            <description>Participants received an infusion of VRC01 at Day 0 and Week 3 and an infusion of placebo at Weeks 6 and 9.
VRC01: 40 mg/kg of VRC01 administered as an intravenous infusion over about 30 to 60 minutes using a volumetric pump
Placebo: Normal saline administered as an intravenous infusion over about 30 to 60 minutes using a volumetric pump</description>
          </group>
          <group group_id="O2">
            <title>Arm B: Placebo Followed by VRC01</title>
            <description>Participants received an infusion of placebo at Day 0 and Week 3 and an infusion of VRC01 at Weeks 6 and 9.
VRC01: 40 mg/kg of VRC01 administered as an intravenous infusion over about 30 to 60 minutes using a volumetric pump
Placebo: Normal saline administered as an intravenous infusion over about 30 to 60 minutes using a volumetric pump</description>
          </group>
        </group_list>
        <measure>
          <title>CD4+ T-cell Counts</title>
          <description>Baseline measure represents the average of screening and entry results</description>
          <population>Analysis of all participants with available CD4+ results</population>
          <units>cells/mm^3</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="701" lower_limit="594" upper_limit="952"/>
                    <measurement group_id="O2" value="685" lower_limit="535" upper_limit="843"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="709" lower_limit="564" upper_limit="995"/>
                    <measurement group_id="O2" value="697" lower_limit="532" upper_limit="807"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="734" lower_limit="616" upper_limit="886"/>
                    <measurement group_id="O2" value="671" lower_limit="513" upper_limit="873"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 18</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="709" lower_limit="529" upper_limit="885"/>
                    <measurement group_id="O2" value="672" lower_limit="475" upper_limit="844"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 30</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="750" lower_limit="612" upper_limit="1025"/>
                    <measurement group_id="O2" value="712" lower_limit="486" upper_limit="806"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CD8+ T-cell Counts</title>
        <description>Baseline measure represents the average of screening and entry results</description>
        <time_frame>Measured at screening, entry and weeks 6, 12, 18 and 30</time_frame>
        <population>Analysis of all participants with available CD8+ results</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A: VRC01 Followed by Placebo</title>
            <description>Participants received an infusion of VRC01 at Day 0 and Week 3 and an infusion of placebo at Weeks 6 and 9.
VRC01: 40 mg/kg of VRC01 administered as an intravenous infusion over about 30 to 60 minutes using a volumetric pump
Placebo: Normal saline administered as an intravenous infusion over about 30 to 60 minutes using a volumetric pump</description>
          </group>
          <group group_id="O2">
            <title>Arm B: Placebo Followed by VRC01</title>
            <description>Participants received an infusion of placebo at Day 0 and Week 3 and an infusion of VRC01 at Weeks 6 and 9.
VRC01: 40 mg/kg of VRC01 administered as an intravenous infusion over about 30 to 60 minutes using a volumetric pump
Placebo: Normal saline administered as an intravenous infusion over about 30 to 60 minutes using a volumetric pump</description>
          </group>
        </group_list>
        <measure>
          <title>CD8+ T-cell Counts</title>
          <description>Baseline measure represents the average of screening and entry results</description>
          <population>Analysis of all participants with available CD8+ results</population>
          <units>cells/mm^3</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="801" lower_limit="490" upper_limit="1210"/>
                    <measurement group_id="O2" value="617" lower_limit="480" upper_limit="744"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="688" lower_limit="469" upper_limit="977"/>
                    <measurement group_id="O2" value="614" lower_limit="481" upper_limit="825"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="649" lower_limit="508" upper_limit="1039"/>
                    <measurement group_id="O2" value="620" lower_limit="439" upper_limit="852"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 18</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="766" lower_limit="495" upper_limit="1214"/>
                    <measurement group_id="O2" value="665" lower_limit="421" upper_limit="766"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 30</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="731" lower_limit="551" upper_limit="990"/>
                    <measurement group_id="O2" value="655" lower_limit="436" upper_limit="740"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total/Inducible Virus Recovery - Stimulated HIV-1 RNA</title>
        <description>As part of the total virus recovery assay, results for stimulated HIV-1 RNA (copies/mL) are generated</description>
        <time_frame>Measured at pre-entry, week 6 and week 12</time_frame>
        <population>Includes all participants with available stimulated HIV-1 RNA results from virus recovery assay</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A: VRC01 Followed by Placebo</title>
            <description>Participants received an infusion of VRC01 at Day 0 and Week 3 and an infusion of placebo at Weeks 6 and 9.
VRC01: 40 mg/kg of VRC01 administered as an intravenous infusion over about 30 to 60 minutes using a volumetric pump
Placebo: Normal saline administered as an intravenous infusion over about 30 to 60 minutes using a volumetric pump</description>
          </group>
          <group group_id="O2">
            <title>Arm B: Placebo Followed by VRC01</title>
            <description>Participants received an infusion of placebo at Day 0 and Week 3 and an infusion of VRC01 at Weeks 6 and 9.
VRC01: 40 mg/kg of VRC01 administered as an intravenous infusion over about 30 to 60 minutes using a volumetric pump
Placebo: Normal saline administered as an intravenous infusion over about 30 to 60 minutes using a volumetric pump</description>
          </group>
        </group_list>
        <measure>
          <title>Total/Inducible Virus Recovery - Stimulated HIV-1 RNA</title>
          <description>As part of the total virus recovery assay, results for stimulated HIV-1 RNA (copies/mL) are generated</description>
          <population>Includes all participants with available stimulated HIV-1 RNA results from virus recovery assay</population>
          <units>log10 copies/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre-entry</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.83" lower_limit="1.81" upper_limit="3.16"/>
                    <measurement group_id="O2" value="2.85" lower_limit="2.28" upper_limit="3.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.74" lower_limit="2.31" upper_limit="3.41"/>
                    <measurement group_id="O2" value="3.12" lower_limit="2.11" upper_limit="3.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.74" lower_limit="2.53" upper_limit="3.18"/>
                    <measurement group_id="O2" value="2.63" lower_limit="2.27" upper_limit="3.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total/Inducible Virus Recovery - Unstimulated HIV-1 RNA</title>
        <description>As part of the total virus recovery assay, results for unstimulated HIV-1 RNA (copies/mL) are generated</description>
        <time_frame>Measured at pre-entry, week 6 and week 12</time_frame>
        <population>Includes all participants with available unstimulated HIV-1 RNA results from virus recovery assay</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A: VRC01 Followed by Placebo</title>
            <description>Participants received an infusion of VRC01 at Day 0 and Week 3 and an infusion of placebo at Weeks 6 and 9.
VRC01: 40 mg/kg of VRC01 administered as an intravenous infusion over about 30 to 60 minutes using a volumetric pump
Placebo: Normal saline administered as an intravenous infusion over about 30 to 60 minutes using a volumetric pump</description>
          </group>
          <group group_id="O2">
            <title>Arm B: Placebo Followed by VRC01</title>
            <description>Participants received an infusion of placebo at Day 0 and Week 3 and an infusion of VRC01 at Weeks 6 and 9.
VRC01: 40 mg/kg of VRC01 administered as an intravenous infusion over about 30 to 60 minutes using a volumetric pump
Placebo: Normal saline administered as an intravenous infusion over about 30 to 60 minutes using a volumetric pump</description>
          </group>
        </group_list>
        <measure>
          <title>Total/Inducible Virus Recovery - Unstimulated HIV-1 RNA</title>
          <description>As part of the total virus recovery assay, results for unstimulated HIV-1 RNA (copies/mL) are generated</description>
          <population>Includes all participants with available unstimulated HIV-1 RNA results from virus recovery assay</population>
          <units>log10 copies/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre-entry</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.00" lower_limit="0.50" upper_limit="1.86"/>
                    <measurement group_id="O2" value="1.00" lower_limit="0.00" upper_limit="1.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.44" lower_limit="0.71" upper_limit="1.95"/>
                    <measurement group_id="O2" value="0.92" lower_limit="0.00" upper_limit="1.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.25" lower_limit="0.50" upper_limit="1.90"/>
                    <measurement group_id="O2" value="1.53" lower_limit="1.00" upper_limit="2.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total/Inducible Virus Recovery - Stimulated to Unstimulated HIV-1 RNA Ratio</title>
        <description>As part of the total virus recovery assay, results for stimulated and unstimulated HIV-1 RNA (copies/mL) are generated. At each time point, the ratio of the stimulated to unstimulated HIV-1 RNA was calculated.</description>
        <time_frame>Measured at pre-entry, week 6 and week 12</time_frame>
        <population>Includes all participants with available stimulated/unstimulated HIV-1 RNA results from virus recovery assay</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A: VRC01 Followed by Placebo</title>
            <description>Participants received an infusion of VRC01 at Day 0 and Week 3 and an infusion of placebo at Weeks 6 and 9.
VRC01: 40 mg/kg of VRC01 administered as an intravenous infusion over about 30 to 60 minutes using a volumetric pump
Placebo: Normal saline administered as an intravenous infusion over about 30 to 60 minutes using a volumetric pump</description>
          </group>
          <group group_id="O2">
            <title>Arm B: Placebo Followed by VRC01</title>
            <description>Participants received an infusion of placebo at Day 0 and Week 3 and an infusion of VRC01 at Weeks 6 and 9.
VRC01: 40 mg/kg of VRC01 administered as an intravenous infusion over about 30 to 60 minutes using a volumetric pump
Placebo: Normal saline administered as an intravenous infusion over about 30 to 60 minutes using a volumetric pump</description>
          </group>
        </group_list>
        <measure>
          <title>Total/Inducible Virus Recovery - Stimulated to Unstimulated HIV-1 RNA Ratio</title>
          <description>As part of the total virus recovery assay, results for stimulated and unstimulated HIV-1 RNA (copies/mL) are generated. At each time point, the ratio of the stimulated to unstimulated HIV-1 RNA was calculated.</description>
          <population>Includes all participants with available stimulated/unstimulated HIV-1 RNA results from virus recovery assay</population>
          <units>ratio</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre-entry</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.73" lower_limit="4.76" upper_limit="104.29"/>
                    <measurement group_id="O2" value="25.49" lower_limit="8.12" upper_limit="115.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.03" lower_limit="5.58" upper_limit="78.37"/>
                    <measurement group_id="O2" value="40.50" lower_limit="10.77" upper_limit="759.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.12" lower_limit="5.57" upper_limit="93.90"/>
                    <measurement group_id="O2" value="16.09" lower_limit="9.00" upper_limit="43.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total/Inducible Virus Recovery - Stimulated Cell Fluor</title>
        <description>As part of the total virus recovery assay, results for stimulated cell fluor (light units) are generated.</description>
        <time_frame>Measured at pre-entry, week 6 and week 12</time_frame>
        <population>Includes all participants with available stimulated cell fluor results from virus recovery assay</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A: VRC01 Followed by Placebo</title>
            <description>Participants received an infusion of VRC01 at Day 0 and Week 3 and an infusion of placebo at Weeks 6 and 9.
VRC01: 40 mg/kg of VRC01 administered as an intravenous infusion over about 30 to 60 minutes using a volumetric pump
Placebo: Normal saline administered as an intravenous infusion over about 30 to 60 minutes using a volumetric pump</description>
          </group>
          <group group_id="O2">
            <title>Arm B: Placebo Followed by VRC01</title>
            <description>Participants received an infusion of placebo at Day 0 and Week 3 and an infusion of VRC01 at Weeks 6 and 9.
VRC01: 40 mg/kg of VRC01 administered as an intravenous infusion over about 30 to 60 minutes using a volumetric pump
Placebo: Normal saline administered as an intravenous infusion over about 30 to 60 minutes using a volumetric pump</description>
          </group>
        </group_list>
        <measure>
          <title>Total/Inducible Virus Recovery - Stimulated Cell Fluor</title>
          <description>As part of the total virus recovery assay, results for stimulated cell fluor (light units) are generated.</description>
          <population>Includes all participants with available stimulated cell fluor results from virus recovery assay</population>
          <units>million light units</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre-entry</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.86" lower_limit="22.14" upper_limit="30.42"/>
                    <measurement group_id="O2" value="26.05" lower_limit="21.42" upper_limit="30.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.68" lower_limit="22.00" upper_limit="30.09"/>
                    <measurement group_id="O2" value="26.13" lower_limit="21.79" upper_limit="29.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.38" lower_limit="22.12" upper_limit="31.25"/>
                    <measurement group_id="O2" value="26.97" lower_limit="22.57" upper_limit="32.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total/Inducible Virus Recovery - Unstimulated Cell Fluor</title>
        <description>As part of the total virus recovery assay, results for unstimulated cell fluor (light units) are generated.</description>
        <time_frame>Measured at pre-entry, week 6 and week 12</time_frame>
        <population>Includes all participants with available unstimulated cell fluor results from virus recovery assay</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A: VRC01 Followed by Placebo</title>
            <description>Participants received an infusion of VRC01 at Day 0 and Week 3 and an infusion of placebo at Weeks 6 and 9.
VRC01: 40 mg/kg of VRC01 administered as an intravenous infusion over about 30 to 60 minutes using a volumetric pump
Placebo: Normal saline administered as an intravenous infusion over about 30 to 60 minutes using a volumetric pump</description>
          </group>
          <group group_id="O2">
            <title>Arm B: Placebo Followed by VRC01</title>
            <description>Participants received an infusion of placebo at Day 0 and Week 3 and an infusion of VRC01 at Weeks 6 and 9.
VRC01: 40 mg/kg of VRC01 administered as an intravenous infusion over about 30 to 60 minutes using a volumetric pump
Placebo: Normal saline administered as an intravenous infusion over about 30 to 60 minutes using a volumetric pump</description>
          </group>
        </group_list>
        <measure>
          <title>Total/Inducible Virus Recovery - Unstimulated Cell Fluor</title>
          <description>As part of the total virus recovery assay, results for unstimulated cell fluor (light units) are generated.</description>
          <population>Includes all participants with available unstimulated cell fluor results from virus recovery assay</population>
          <units>million light units</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre-entry</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.86" lower_limit="5.70" upper_limit="13.34"/>
                    <measurement group_id="O2" value="5.87" lower_limit="4.57" upper_limit="6.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.39" lower_limit="4.94" upper_limit="8.01"/>
                    <measurement group_id="O2" value="6.22" lower_limit="5.00" upper_limit="8.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.53" lower_limit="6.20" upper_limit="12.16"/>
                    <measurement group_id="O2" value="6.27" lower_limit="5.05" upper_limit="8.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total/Inducible Virus Recovery - Stimulated to Unstimulated Cell Fluor Ratio</title>
        <description>As part of the total virus recovery assay, results for stimulated and unstimulated cell fluor (light units) are generated. At each time point, the ratio of the stimulated to unstimulated cell fluor was calculated.</description>
        <time_frame>Measured at pre-entry, week 6 and week 12</time_frame>
        <population>Includes all participants with available stimulated/unstimulated cell fluor results from virus recovery assay</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A: VRC01 Followed by Placebo</title>
            <description>Participants received an infusion of VRC01 at Day 0 and Week 3 and an infusion of placebo at Weeks 6 and 9.
VRC01: 40 mg/kg of VRC01 administered as an intravenous infusion over about 30 to 60 minutes using a volumetric pump
Placebo: Normal saline administered as an intravenous infusion over about 30 to 60 minutes using a volumetric pump</description>
          </group>
          <group group_id="O2">
            <title>Arm B: Placebo Followed by VRC01</title>
            <description>Participants received an infusion of placebo at Day 0 and Week 3 and an infusion of VRC01 at Weeks 6 and 9.
VRC01: 40 mg/kg of VRC01 administered as an intravenous infusion over about 30 to 60 minutes using a volumetric pump
Placebo: Normal saline administered as an intravenous infusion over about 30 to 60 minutes using a volumetric pump</description>
          </group>
        </group_list>
        <measure>
          <title>Total/Inducible Virus Recovery - Stimulated to Unstimulated Cell Fluor Ratio</title>
          <description>As part of the total virus recovery assay, results for stimulated and unstimulated cell fluor (light units) are generated. At each time point, the ratio of the stimulated to unstimulated cell fluor was calculated.</description>
          <population>Includes all participants with available stimulated/unstimulated cell fluor results from virus recovery assay</population>
          <units>ratio</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre-entry</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.91" lower_limit="2.14" upper_limit="4.65"/>
                    <measurement group_id="O2" value="4.32" lower_limit="3.60" upper_limit="5.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.20" lower_limit="3.04" upper_limit="4.78"/>
                    <measurement group_id="O2" value="3.87" lower_limit="3.36" upper_limit="5.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.33" lower_limit="2.16" upper_limit="4.62"/>
                    <measurement group_id="O2" value="3.76" lower_limit="3.52" upper_limit="4.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total/Inducible Virus Recovery - Percentage of Total CD4 Yield</title>
        <description>As part of the total virus recovery assay, results for %tCD4 yield are generated.</description>
        <time_frame>Measured at pre-entry, week 6 and week 12</time_frame>
        <population>Includes all participants with available %tCD4 yield results from virus recovery assay</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A: VRC01 Followed by Placebo</title>
            <description>Participants received an infusion of VRC01 at Day 0 and Week 3 and an infusion of placebo at Weeks 6 and 9.
VRC01: 40 mg/kg of VRC01 administered as an intravenous infusion over about 30 to 60 minutes using a volumetric pump
Placebo: Normal saline administered as an intravenous infusion over about 30 to 60 minutes using a volumetric pump</description>
          </group>
          <group group_id="O2">
            <title>Arm B: Placebo Followed by VRC01</title>
            <description>Participants received an infusion of placebo at Day 0 and Week 3 and an infusion of VRC01 at Weeks 6 and 9.
VRC01: 40 mg/kg of VRC01 administered as an intravenous infusion over about 30 to 60 minutes using a volumetric pump
Placebo: Normal saline administered as an intravenous infusion over about 30 to 60 minutes using a volumetric pump</description>
          </group>
        </group_list>
        <measure>
          <title>Total/Inducible Virus Recovery - Percentage of Total CD4 Yield</title>
          <description>As part of the total virus recovery assay, results for %tCD4 yield are generated.</description>
          <population>Includes all participants with available %tCD4 yield results from virus recovery assay</population>
          <units>percentage of Total CD4 Yield</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre-entry</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.35" lower_limit="20.00" upper_limit="32.17"/>
                    <measurement group_id="O2" value="22.00" lower_limit="19.00" upper_limit="27.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.00" lower_limit="18.00" upper_limit="32.14"/>
                    <measurement group_id="O2" value="22.38" lower_limit="17.65" upper_limit="33.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.00" lower_limit="21.00" upper_limit="30.32"/>
                    <measurement group_id="O2" value="22.58" lower_limit="18.81" upper_limit="29.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Total/Inducible Virus Recovery - Stimulated HIV-1 RNA</title>
        <description>As part of the total virus recovery assay, results for stimulated HIV-1 RNA (copies/mL) are generated. The change from the pre-treatment time point to week 6 was assessed as a fold change (week 6 / pre-entry)</description>
        <time_frame>Measured at pre-entry, week 6</time_frame>
        <population>Includes all participants with available stimulated HIV-1 RNA results from virus recovery assay at pre-entry and week 6 time points</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A: VRC01 Followed by Placebo</title>
            <description>Participants received an infusion of VRC01 at Day 0 and Week 3 and an infusion of placebo at Weeks 6 and 9.
VRC01: 40 mg/kg of VRC01 administered as an intravenous infusion over about 30 to 60 minutes using a volumetric pump
Placebo: Normal saline administered as an intravenous infusion over about 30 to 60 minutes using a volumetric pump</description>
          </group>
          <group group_id="O2">
            <title>Arm B: Placebo Followed by VRC01</title>
            <description>Participants received an infusion of placebo at Day 0 and Week 3 and an infusion of VRC01 at Weeks 6 and 9.
VRC01: 40 mg/kg of VRC01 administered as an intravenous infusion over about 30 to 60 minutes using a volumetric pump
Placebo: Normal saline administered as an intravenous infusion over about 30 to 60 minutes using a volumetric pump</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Total/Inducible Virus Recovery - Stimulated HIV-1 RNA</title>
          <description>As part of the total virus recovery assay, results for stimulated HIV-1 RNA (copies/mL) are generated. The change from the pre-treatment time point to week 6 was assessed as a fold change (week 6 / pre-entry)</description>
          <population>Includes all participants with available stimulated HIV-1 RNA results from virus recovery assay at pre-entry and week 6 time points</population>
          <units>fold change</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.74" lower_limit="0.31" upper_limit="8.38"/>
                    <measurement group_id="O2" value="1.32" lower_limit="0.30" upper_limit="1.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Total/Inducible Virus Recovery - Unstimulated HIV-1 RNA</title>
        <description>As part of the total virus recovery assay, results for unstimulated HIV-1 RNA (copies/mL) are generated. The change from the pre-treatment time point to week 6 was assessed as a fold change (week 6 / pre-entry)</description>
        <time_frame>Measured at pre-entry, week 6</time_frame>
        <population>Includes all participants with available unstimulated HIV-1 RNA results from virus recovery assay at pre-entry and week 6 time points</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A: VRC01 Followed by Placebo</title>
            <description>Participants received an infusion of VRC01 at Day 0 and Week 3 and an infusion of placebo at Weeks 6 and 9.
VRC01: 40 mg/kg of VRC01 administered as an intravenous infusion over about 30 to 60 minutes using a volumetric pump
Placebo: Normal saline administered as an intravenous infusion over about 30 to 60 minutes using a volumetric pump</description>
          </group>
          <group group_id="O2">
            <title>Arm B: Placebo Followed by VRC01</title>
            <description>Participants received an infusion of placebo at Day 0 and Week 3 and an infusion of VRC01 at Weeks 6 and 9.
VRC01: 40 mg/kg of VRC01 administered as an intravenous infusion over about 30 to 60 minutes using a volumetric pump
Placebo: Normal saline administered as an intravenous infusion over about 30 to 60 minutes using a volumetric pump</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Total/Inducible Virus Recovery - Unstimulated HIV-1 RNA</title>
          <description>As part of the total virus recovery assay, results for unstimulated HIV-1 RNA (copies/mL) are generated. The change from the pre-treatment time point to week 6 was assessed as a fold change (week 6 / pre-entry)</description>
          <population>Includes all participants with available unstimulated HIV-1 RNA results from virus recovery assay at pre-entry and week 6 time points</population>
          <units>fold change</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.37" lower_limit="1.00" upper_limit="2.11"/>
                    <measurement group_id="O2" value="1.00" lower_limit="0.19" upper_limit="2.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Total/Inducible Virus Recovery - Stimulated to Unstimulated HIV-1 RNA Ratio</title>
        <description>As part of the total virus recovery assay, results for stimulated and unstimulated HIV-1 RNA (copies/mL) are generated. At each time point, the ratio of the stimulated to unstimulated HIV-1 RNA was calculated. The fold change of this ratio from pre-entry to the week 6 time point was calculated for each arm (week 6 / pre-entry)</description>
        <time_frame>Measured at pre-entry and week 6</time_frame>
        <population>Includes all participants with available stimulated/unstimulated HIV-1 RNA results from virus recovery assay</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A: VRC01 Followed by Placebo</title>
            <description>Participants received an infusion of VRC01 at Day 0 and Week 3 and an infusion of placebo at Weeks 6 and 9.
VRC01: 40 mg/kg of VRC01 administered as an intravenous infusion over about 30 to 60 minutes using a volumetric pump
Placebo: Normal saline administered as an intravenous infusion over about 30 to 60 minutes using a volumetric pump</description>
          </group>
          <group group_id="O2">
            <title>Arm B: Placebo Followed by VRC01</title>
            <description>Participants received an infusion of placebo at Day 0 and Week 3 and an infusion of VRC01 at Weeks 6 and 9.
VRC01: 40 mg/kg of VRC01 administered as an intravenous infusion over about 30 to 60 minutes using a volumetric pump
Placebo: Normal saline administered as an intravenous infusion over about 30 to 60 minutes using a volumetric pump</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Total/Inducible Virus Recovery - Stimulated to Unstimulated HIV-1 RNA Ratio</title>
          <description>As part of the total virus recovery assay, results for stimulated and unstimulated HIV-1 RNA (copies/mL) are generated. At each time point, the ratio of the stimulated to unstimulated HIV-1 RNA was calculated. The fold change of this ratio from pre-entry to the week 6 time point was calculated for each arm (week 6 / pre-entry)</description>
          <population>Includes all participants with available stimulated/unstimulated HIV-1 RNA results from virus recovery assay</population>
          <units>fold change</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.69" lower_limit="0.20" upper_limit="3.71"/>
                    <measurement group_id="O2" value="0.85" lower_limit="0.21" upper_limit="12.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Total/Inducible Virus Recovery - Stimulated Cell Fluor</title>
        <description>As part of the total virus recovery assay, results for stimulated cell fluor (light units) are generated. The fold change from pre-entry to the week 6 time point was calculated for each arm (week 6 / pre-entry)</description>
        <time_frame>Measured at pre-entry, week 6</time_frame>
        <population>Includes all participants with available stimulated cell fluor results from virus recovery assay at pre-entry and week 6 time points</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A: VRC01 Followed by Placebo</title>
            <description>Participants received an infusion of VRC01 at Day 0 and Week 3 and an infusion of placebo at Weeks 6 and 9.
VRC01: 40 mg/kg of VRC01 administered as an intravenous infusion over about 30 to 60 minutes using a volumetric pump
Placebo: Normal saline administered as an intravenous infusion over about 30 to 60 minutes using a volumetric pump</description>
          </group>
          <group group_id="O2">
            <title>Arm B: Placebo Followed by VRC01</title>
            <description>Participants received an infusion of placebo at Day 0 and Week 3 and an infusion of VRC01 at Weeks 6 and 9.
VRC01: 40 mg/kg of VRC01 administered as an intravenous infusion over about 30 to 60 minutes using a volumetric pump
Placebo: Normal saline administered as an intravenous infusion over about 30 to 60 minutes using a volumetric pump</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Total/Inducible Virus Recovery - Stimulated Cell Fluor</title>
          <description>As part of the total virus recovery assay, results for stimulated cell fluor (light units) are generated. The fold change from pre-entry to the week 6 time point was calculated for each arm (week 6 / pre-entry)</description>
          <population>Includes all participants with available stimulated cell fluor results from virus recovery assay at pre-entry and week 6 time points</population>
          <units>fold change</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.97" lower_limit="0.91" upper_limit="1.09"/>
                    <measurement group_id="O2" value="0.97" lower_limit="0.92" upper_limit="1.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Total/Inducible Virus Recovery - Unstimulated Cell Fluor</title>
        <description>As part of the total virus recovery assay, results for unstimulated cell fluor (light units) are generated. The fold change from pre-entry to the week 6 time point was calculated for each arm (week 6 / pre-entry)</description>
        <time_frame>Measured at pre-entry, week 6</time_frame>
        <population>Includes all participants with available unstimulated cell fluor results from virus recovery assay at pre-entry and week 6 time points</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A: VRC01 Followed by Placebo</title>
            <description>Participants received an infusion of VRC01 at Day 0 and Week 3 and an infusion of placebo at Weeks 6 and 9.
VRC01: 40 mg/kg of VRC01 administered as an intravenous infusion over about 30 to 60 minutes using a volumetric pump
Placebo: Normal saline administered as an intravenous infusion over about 30 to 60 minutes using a volumetric pump</description>
          </group>
          <group group_id="O2">
            <title>Arm B: Placebo Followed by VRC01</title>
            <description>Participants received an infusion of placebo at Day 0 and Week 3 and an infusion of VRC01 at Weeks 6 and 9.
VRC01: 40 mg/kg of VRC01 administered as an intravenous infusion over about 30 to 60 minutes using a volumetric pump
Placebo: Normal saline administered as an intravenous infusion over about 30 to 60 minutes using a volumetric pump</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Total/Inducible Virus Recovery - Unstimulated Cell Fluor</title>
          <description>As part of the total virus recovery assay, results for unstimulated cell fluor (light units) are generated. The fold change from pre-entry to the week 6 time point was calculated for each arm (week 6 / pre-entry)</description>
          <population>Includes all participants with available unstimulated cell fluor results from virus recovery assay at pre-entry and week 6 time points</population>
          <units>fold change</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.93" lower_limit="0.66" upper_limit="1.15"/>
                    <measurement group_id="O2" value="1.12" lower_limit="1.02" upper_limit="1.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Total/Inducible Virus Recovery - Stimulated to Unstimulated Cell Fluor Ratio</title>
        <description>As part of the total virus recovery assay, results for stimulated and unstimulated cell fluor (light units) are generated. At each time point, the ratio of the stimulated to unstimulated cell fluor was calculated. The fold change of this ratio from pre-entry to the week 6 time point was calculated for each arm (week 6 / pre-entry)</description>
        <time_frame>Measured at pre-entry, week 6</time_frame>
        <population>Includes all participants with available stimulated/unstimulated cell fluor results from virus recovery assay at pre-entry and week 6 time points</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A: VRC01 Followed by Placebo</title>
            <description>Participants received an infusion of VRC01 at Day 0 and Week 3 and an infusion of placebo at Weeks 6 and 9.
VRC01: 40 mg/kg of VRC01 administered as an intravenous infusion over about 30 to 60 minutes using a volumetric pump
Placebo: Normal saline administered as an intravenous infusion over about 30 to 60 minutes using a volumetric pump</description>
          </group>
          <group group_id="O2">
            <title>Arm B: Placebo Followed by VRC01</title>
            <description>Participants received an infusion of placebo at Day 0 and Week 3 and an infusion of VRC01 at Weeks 6 and 9.
VRC01: 40 mg/kg of VRC01 administered as an intravenous infusion over about 30 to 60 minutes using a volumetric pump
Placebo: Normal saline administered as an intravenous infusion over about 30 to 60 minutes using a volumetric pump</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Total/Inducible Virus Recovery - Stimulated to Unstimulated Cell Fluor Ratio</title>
          <description>As part of the total virus recovery assay, results for stimulated and unstimulated cell fluor (light units) are generated. At each time point, the ratio of the stimulated to unstimulated cell fluor was calculated. The fold change of this ratio from pre-entry to the week 6 time point was calculated for each arm (week 6 / pre-entry)</description>
          <population>Includes all participants with available stimulated/unstimulated cell fluor results from virus recovery assay at pre-entry and week 6 time points</population>
          <units>fold change</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.08" lower_limit="0.84" upper_limit="1.64"/>
                    <measurement group_id="O2" value="0.85" lower_limit="0.73" upper_limit="1.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Total/Inducible Virus Recovery - Percentage of Total CD4 Yield</title>
        <description>As part of the total virus recovery assay, results for %tCD4 yield are generated. The fold change from pre-entry to the week 6 time point was calculated for each arm (week 6 / pre-entry)</description>
        <time_frame>Measured at pre-entry, week 6</time_frame>
        <population>Includes all participants with available %tCD4 yield results from virus recovery assay at pre-entry and week 6 time points</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A: VRC01 Followed by Placebo</title>
            <description>Participants received an infusion of VRC01 at Day 0 and Week 3 and an infusion of placebo at Weeks 6 and 9.
VRC01: 40 mg/kg of VRC01 administered as an intravenous infusion over about 30 to 60 minutes using a volumetric pump
Placebo: Normal saline administered as an intravenous infusion over about 30 to 60 minutes using a volumetric pump</description>
          </group>
          <group group_id="O2">
            <title>Arm B: Placebo Followed by VRC01</title>
            <description>Participants received an infusion of placebo at Day 0 and Week 3 and an infusion of VRC01 at Weeks 6 and 9.
VRC01: 40 mg/kg of VRC01 administered as an intravenous infusion over about 30 to 60 minutes using a volumetric pump
Placebo: Normal saline administered as an intravenous infusion over about 30 to 60 minutes using a volumetric pump</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Total/Inducible Virus Recovery - Percentage of Total CD4 Yield</title>
          <description>As part of the total virus recovery assay, results for %tCD4 yield are generated. The fold change from pre-entry to the week 6 time point was calculated for each arm (week 6 / pre-entry)</description>
          <population>Includes all participants with available %tCD4 yield results from virus recovery assay at pre-entry and week 6 time points</population>
          <units>fold change</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.00" lower_limit="0.81" upper_limit="1.41"/>
                    <measurement group_id="O2" value="1.06" lower_limit="0.77" upper_limit="1.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>VRC01 Antibody Level</title>
        <description>Summarize the pharmacokinetics (PK) of two infusions of VRC01 during study follow up
Specific specimens and time points were targeted for testing based on Arm. Samples for Arm A were not tested for the Week 6 and Week 9 post-infusion time points. Samples for Arm B were not tested for the Week 0 and Week 3 post-infusion time points.</description>
        <time_frame>Measured at entry and weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 15, 18 and 30</time_frame>
        <population>Analysis of all participants with available results.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A: VRC01 Followed by Placebo</title>
            <description>Participants received an infusion of VRC01 at Day 0 and Week 3 and an infusion of placebo (normal saline) at Weeks 6 and 9.
VRC01: 40 mg/kg of VRC01 administered as an intravenous infusion over about 30 to 60 minutes using a volumetric pump
Placebo: Normal saline administered as an intravenous infusion over about 30 to 60 minutes using a volumetric pump</description>
          </group>
          <group group_id="O2">
            <title>Arm B: Placebo Followed by VRC01</title>
            <description>Participants received an infusion of placebo (normal saline) at Day 0 and Week 3 and an infusion of VRC01 at Weeks 6 and 9.
VRC01: 40 mg/kg of VRC01 administered as an intravenous infusion over about 30 to 60 minutes using a volumetric pump
Placebo: Normal saline administered as an intravenous infusion over about 30 to 60 minutes using a volumetric pump</description>
          </group>
        </group_list>
        <measure>
          <title>VRC01 Antibody Level</title>
          <description>Summarize the pharmacokinetics (PK) of two infusions of VRC01 during study follow up
Specific specimens and time points were targeted for testing based on Arm. Samples for Arm A were not tested for the Week 6 and Week 9 post-infusion time points. Samples for Arm B were not tested for the Week 0 and Week 3 post-infusion time points.</description>
          <population>Analysis of all participants with available results.</population>
          <units>ug/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 0 - Pre-Infusion</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" lower_limit="0.1" upper_limit="0.1"/>
                    <measurement group_id="O2" value="0.1" lower_limit="0.1" upper_limit="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 0 - Post-Infusion</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1726.2" lower_limit="1492.5" upper_limit="1950.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="259.9" lower_limit="213.0" upper_limit="297.5"/>
                    <measurement group_id="O2" value="0.1" lower_limit="0.1" upper_limit="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="147.4" lower_limit="123.3" upper_limit="182.1"/>
                    <measurement group_id="O2" value="0.1" lower_limit="0.1" upper_limit="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 3 - Pre-Infusion</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="113.6" lower_limit="102.2" upper_limit="130.0"/>
                    <measurement group_id="O2" value="0.1" lower_limit="0.1" upper_limit="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 3 - Post-Infusion</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1807.7" lower_limit="1617.0" upper_limit="2105.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="361.9" lower_limit="295.4" upper_limit="432.3"/>
                    <measurement group_id="O2" value="0.1" lower_limit="0.1" upper_limit="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="216.9" lower_limit="174.6" upper_limit="254.2"/>
                    <measurement group_id="O2" value="0.1" lower_limit="0.1" upper_limit="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 - Pre-Infusion</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="135.8" lower_limit="112.2" upper_limit="164.5"/>
                    <measurement group_id="O2" value="0.1" lower_limit="0.1" upper_limit="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 - Post-Infusion</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="1643.5" lower_limit="1483.3" upper_limit="2041.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.9" lower_limit="63.4" upper_limit="119.2"/>
                    <measurement group_id="O2" value="277.7" lower_limit="240.7" upper_limit="318.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.2" lower_limit="35.5" upper_limit="82.7"/>
                    <measurement group_id="O2" value="158.0" lower_limit="126.6" upper_limit="193.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 9 - Pre-Infusion</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.1" lower_limit="21.1" upper_limit="56.8"/>
                    <measurement group_id="O2" value="98.7" lower_limit="82.8" upper_limit="167.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 9 - Post-Infusion</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="1717.8" lower_limit="1446.9" upper_limit="2153.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 10</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.8" lower_limit="27.6" upper_limit="47.4"/>
                    <measurement group_id="O2" value="373.8" lower_limit="302.3" upper_limit="416.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 11</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.3" lower_limit="10.4" upper_limit="28.1"/>
                    <measurement group_id="O2" value="217.2" lower_limit="178.0" upper_limit="301.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.4" lower_limit="6.3" upper_limit="25.1"/>
                    <measurement group_id="O2" value="131.1" lower_limit="106.3" upper_limit="215.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 15</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.0" lower_limit="1.9" upper_limit="10.9"/>
                    <measurement group_id="O2" value="42.1" lower_limit="30.6" upper_limit="66.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 18</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1" lower_limit="0.1" upper_limit="5.2"/>
                    <measurement group_id="O2" value="18.3" lower_limit="9.0" upper_limit="45.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 30</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" lower_limit="0.1" upper_limit="0.1"/>
                    <measurement group_id="O2" value="0.1" lower_limit="0.1" upper_limit="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Detectability of Antibody to VRC01 as Measured in Serum</title>
        <description>Assess the detectability of antibody to VRC01 in samples collected during study follow-up. Intended to be result from specimen at week 30 time point. Due to specimen availability, four participants in Arm A had results from specimens from the week 18 time point. Counts provided are number of participants with detectable anti-VRC01 antibody result.</description>
        <time_frame>Measured at week 30</time_frame>
        <population>All participants with results for anti-VRC01 antibody. Two participants did not have results (one from each arm) due to being lost to follow up.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A: VRC01 Followed by Placebo</title>
            <description>Participants received an infusion of VRC01 at Day 0 and Week 3 and an infusion of placebo (normal saline) at Weeks 6 and 9.
VRC01: 40 mg/kg of VRC01 administered as an intravenous infusion over about 30 to 60 minutes using a volumetric pump
Placebo: Normal saline administered as an intravenous infusion over about 30 to 60 minutes using a volumetric pump</description>
          </group>
          <group group_id="O2">
            <title>Arm B: Placebo Followed by VRC01</title>
            <description>Participants received an infusion of placebo (normal saline) at Day 0 and Week 3 and an infusion of VRC01 at Weeks 6 and 9.
VRC01: 40 mg/kg of VRC01 administered as an intravenous infusion over about 30 to 60 minutes using a volumetric pump
Placebo: Normal saline administered as an intravenous infusion over about 30 to 60 minutes using a volumetric pump</description>
          </group>
        </group_list>
        <measure>
          <title>Detectability of Antibody to VRC01 as Measured in Serum</title>
          <description>Assess the detectability of antibody to VRC01 in samples collected during study follow-up. Intended to be result from specimen at week 30 time point. Due to specimen availability, four participants in Arm A had results from specimens from the week 18 time point. Counts provided are number of participants with detectable anti-VRC01 antibody result.</description>
          <population>All participants with results for anti-VRC01 antibody. Two participants did not have results (one from each arm) due to being lost to follow up.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Levels of T-cell Activation</title>
        <description>% CD4+ and CD8+ T-cells co-expressing human leukocyte antigen (HLA)-DR and CD38
Not conducted as part of primary analysis and there are no future plans to assess this outcome. Samples were collected for this outcome in order to assess associations with virologic effects observed. Due to the lack of virologic effect observed, the study team has decided that this outcome is no longer of priority/interest and will be abandoned in favor of saving these samples for future research purposes.</description>
        <time_frame>Measured at screening, entry and weeks 1, 3, 4, 6, 7, 9, 10, 12, 15, 18 and 30</time_frame>
        <population>Analysis not performed. See outcome measure description for reasoning.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A: VRC01 Followed by Placebo</title>
            <description>Participants received an infusion of VRC01 at Day 0 and Week 3 and an infusion of placebo (normal saline) at Weeks 6 and 9.
VRC01: 40 mg/kg of VRC01 administered as an intravenous infusion over about 30 to 60 minutes using a volumetric pump
Placebo: Normal saline administered as an intravenous infusion over about 30 to 60 minutes using a volumetric pump</description>
          </group>
          <group group_id="O2">
            <title>Arm B: Placebo Followed by VRC01</title>
            <description>Participants received an infusion of placebo (normal saline) at Day 0 and Week 3 and an infusion of VRC01 at Weeks 6 and 9.
VRC01: 40 mg/kg of VRC01 administered as an intravenous infusion over about 30 to 60 minutes using a volumetric pump
Placebo: Normal saline administered as an intravenous infusion over about 30 to 60 minutes using a volumetric pump</description>
          </group>
        </group_list>
        <measure>
          <title>Levels of T-cell Activation</title>
          <description>% CD4+ and CD8+ T-cells co-expressing human leukocyte antigen (HLA)-DR and CD38
Not conducted as part of primary analysis and there are no future plans to assess this outcome. Samples were collected for this outcome in order to assess associations with virologic effects observed. Due to the lack of virologic effect observed, the study team has decided that this outcome is no longer of priority/interest and will be abandoned in favor of saving these samples for future research purposes.</description>
          <population>Analysis not performed. See outcome measure description for reasoning.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Levels of NK Cell Activation</title>
        <description>% NK cells expressing CD69 or CD95
Not conducted as part of primary analysis and there are no future plans to assess this outcome. Samples were collected for this outcome in order to assess associations with virologic effects observed. Due to the lack of virologic effect observed, the study team has decided that this outcome is no longer of priority/interest and will be abandoned in favor of saving these samples for future research purposes.</description>
        <time_frame>Measured at screening, entry and weeks 1, 3, 4, 6, 7, 9, 10, 12, 15, 18 and 30</time_frame>
        <population>Analysis not performed. See outcome measure description for reasoning.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A: VRC01 Followed by Placebo</title>
            <description>Participants received an infusion of VRC01 at Day 0 and Week 3 and an infusion of placebo at Weeks 6 and 9.
VRC01: 40 mg/kg of VRC01 administered as an intravenous infusion over about 30 to 60 minutes using a volumetric pump
Placebo: Normal saline administered as an intravenous infusion over about 30 to 60 minutes using a volumetric pump</description>
          </group>
          <group group_id="O2">
            <title>Arm B: Placebo Followed by VRC01</title>
            <description>Participants received an infusion of placebo at Day 0 and Week 3 and an infusion of VRC01 at Weeks 6 and 9.
VRC01: 40 mg/kg of VRC01 administered as an intravenous infusion over about 30 to 60 minutes using a volumetric pump
Placebo: Normal saline administered as an intravenous infusion over about 30 to 60 minutes using a volumetric pump</description>
          </group>
        </group_list>
        <measure>
          <title>Levels of NK Cell Activation</title>
          <description>% NK cells expressing CD69 or CD95
Not conducted as part of primary analysis and there are no future plans to assess this outcome. Samples were collected for this outcome in order to assess associations with virologic effects observed. Due to the lack of virologic effect observed, the study team has decided that this outcome is no longer of priority/interest and will be abandoned in favor of saving these samples for future research purposes.</description>
          <population>Analysis not performed. See outcome measure description for reasoning.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Levels of sCD163</title>
        <description>Not conducted as part of primary analysis and there are no future plans to assess this outcome. Samples were collected for this outcome in order to assess associations with virologic effects observed. Due to the lack of virologic effect observed, the study team has decided that this outcome is no longer of priority/interest and will be abandoned in favor of saving these samples for future research purposes.</description>
        <time_frame>Measured at screening, entry and weeks 1, 3, 4, 6, 7, 9, 10, 12, 15, 18 and 30</time_frame>
        <population>Analysis not performed. See outcome measure description for reasoning.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A: VRC01 Followed by Placebo</title>
            <description>Participants received an infusion of VRC01 at Day 0 and Week 3 and an infusion of placebo at Weeks 6 and 9.
VRC01: 40 mg/kg of VRC01 administered as an intravenous infusion over about 30 to 60 minutes using a volumetric pump
Placebo: Normal saline administered as an intravenous infusion over about 30 to 60 minutes using a volumetric pump</description>
          </group>
          <group group_id="O2">
            <title>Arm B: Placebo Followed by VRC01</title>
            <description>Participants received an infusion of placebo at Day 0 and Week 3 and an infusion of VRC01 at Weeks 6 and 9.
VRC01: 40 mg/kg of VRC01 administered as an intravenous infusion over about 30 to 60 minutes using a volumetric pump
Placebo: Normal saline administered as an intravenous infusion over about 30 to 60 minutes using a volumetric pump</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Levels of sCD163</title>
          <description>Not conducted as part of primary analysis and there are no future plans to assess this outcome. Samples were collected for this outcome in order to assess associations with virologic effects observed. Due to the lack of virologic effect observed, the study team has decided that this outcome is no longer of priority/interest and will be abandoned in favor of saving these samples for future research purposes.</description>
          <population>Analysis not performed. See outcome measure description for reasoning.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Levels of sCD14</title>
        <description>Not conducted as part of primary analysis and there are no future plans to assess this outcome. Samples were collected for this outcome in order to assess associations with virologic effects observed. Due to the lack of virologic effect observed, the study team has decided that this outcome is no longer of priority/interest and will be abandoned in favor of saving these samples for future research purposes.</description>
        <time_frame>Measured at screening, entry and weeks 1, 3, 4, 6, 7, 9, 10, 12, 15, 18 and 30</time_frame>
        <population>Analysis not performed. See outcome measure description for reasoning.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A: VRC01 Followed by Placebo</title>
            <description>Participants received an infusion of VRC01 at Day 0 and Week 3 and an infusion of placebo at Weeks 6 and 9.
VRC01: 40 mg/kg of VRC01 administered as an intravenous infusion over about 30 to 60 minutes using a volumetric pump
Placebo: Normal saline administered as an intravenous infusion over about 30 to 60 minutes using a volumetric pump</description>
          </group>
          <group group_id="O2">
            <title>Arm B: Placebo Followed by VRC01</title>
            <description>Participants received an infusion of placebo at Day 0 and Week 3 and an infusion of VRC01 at Weeks 6 and 9.
VRC01: 40 mg/kg of VRC01 administered as an intravenous infusion over about 30 to 60 minutes using a volumetric pump
Placebo: Normal saline administered as an intravenous infusion over about 30 to 60 minutes using a volumetric pump</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Levels of sCD14</title>
          <description>Not conducted as part of primary analysis and there are no future plans to assess this outcome. Samples were collected for this outcome in order to assess associations with virologic effects observed. Due to the lack of virologic effect observed, the study team has decided that this outcome is no longer of priority/interest and will be abandoned in favor of saving these samples for future research purposes.</description>
          <population>Analysis not performed. See outcome measure description for reasoning.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Levels of Interleukin-6 (IL-6)</title>
        <description>Not conducted as part of primary analysis and there are no future plans to assess this outcome. Samples were collected for this outcome in order to assess associations with virologic effects observed. Due to the lack of virologic effect observed, the study team has decided that this outcome is no longer of priority/interest and will be abandoned in favor of saving these samples for future research purposes.</description>
        <time_frame>Measured at screening, entry and weeks 1, 3, 4, 6, 7, 9, 10, 12, 15, 18 and 30</time_frame>
        <population>Analysis not performed. See outcome measure description for reasoning.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A: VRC01 Followed by Placebo</title>
            <description>Participants received an infusion of VRC01 at Day 0 and Week 3 and an infusion of placebo at Weeks 6 and 9.
VRC01: 40 mg/kg of VRC01 administered as an intravenous infusion over about 30 to 60 minutes using a volumetric pump
Placebo: Normal saline administered as an intravenous infusion over about 30 to 60 minutes using a volumetric pump</description>
          </group>
          <group group_id="O2">
            <title>Arm B: Placebo Followed by VRC01</title>
            <description>Participants received an infusion of placebo at Day 0 and Week 3 and an infusion of VRC01 at Weeks 6 and 9.
VRC01: 40 mg/kg of VRC01 administered as an intravenous infusion over about 30 to 60 minutes using a volumetric pump
Placebo: Normal saline administered as an intravenous infusion over about 30 to 60 minutes using a volumetric pump</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Levels of Interleukin-6 (IL-6)</title>
          <description>Not conducted as part of primary analysis and there are no future plans to assess this outcome. Samples were collected for this outcome in order to assess associations with virologic effects observed. Due to the lack of virologic effect observed, the study team has decided that this outcome is no longer of priority/interest and will be abandoned in favor of saving these samples for future research purposes.</description>
          <population>Analysis not performed. See outcome measure description for reasoning.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Levels of Human Soluble Tumor Necrosis Factor Alpha-receptor (sTNFÎ±R)</title>
        <description>Not conducted as part of primary analysis and there are no future plans to assess this outcome. Samples were collected for this outcome in order to assess associations with virologic effects observed. Due to the lack of virologic effect observed, the study team has decided that this outcome is no longer of priority/interest and will be abandoned in favor of saving these samples for future research purposes.</description>
        <time_frame>Measured at screening, entry and weeks 1, 3, 4, 6, 7, 9, 10, 12, 15, 18 and 30</time_frame>
        <population>Analysis not performed. See outcome measure description for reasoning.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A: VRC01 Followed by Placebo</title>
            <description>Participants received an infusion of VRC01 at Day 0 and Week 3 and an infusion of placebo at Weeks 6 and 9.
VRC01: 40 mg/kg of VRC01 administered as an intravenous infusion over about 30 to 60 minutes using a volumetric pump
Placebo: Normal saline administered as an intravenous infusion over about 30 to 60 minutes using a volumetric pump</description>
          </group>
          <group group_id="O2">
            <title>Arm B: Placebo Followed by VRC01</title>
            <description>Participants received an infusion of placebo at Day 0 and Week 3 and an infusion of VRC01 at Weeks 6 and 9.
VRC01: 40 mg/kg of VRC01 administered as an intravenous infusion over about 30 to 60 minutes using a volumetric pump
Placebo: Normal saline administered as an intravenous infusion over about 30 to 60 minutes using a volumetric pump</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Levels of Human Soluble Tumor Necrosis Factor Alpha-receptor (sTNFÎ±R)</title>
          <description>Not conducted as part of primary analysis and there are no future plans to assess this outcome. Samples were collected for this outcome in order to assess associations with virologic effects observed. Due to the lack of virologic effect observed, the study team has decided that this outcome is no longer of priority/interest and will be abandoned in favor of saving these samples for future research purposes.</description>
          <population>Analysis not performed. See outcome measure description for reasoning.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Levels of Tumor Necrosis Factor Alpha (TNFÎ±)</title>
        <description>Not conducted as part of primary analysis and there are no future plans to assess this outcome. Samples were collected for this outcome in order to assess associations with virologic effects observed. Due to the lack of virologic effect observed, the study team has decided that this outcome is no longer of priority/interest and will be abandoned in favor of saving these samples for future research purposes.</description>
        <time_frame>Measured at screening, entry and weeks 1, 3, 4, 6, 7, 9, 10, 12, 15, 18 and 30</time_frame>
        <population>Analysis not performed. See outcome measure description for reasoning.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A: VRC01 Followed by Placebo</title>
            <description>Participants received an infusion of VRC01 at Day 0 and Week 3 and an infusion of placebo at Weeks 6 and 9.
VRC01: 40 mg/kg of VRC01 administered as an intravenous infusion over about 30 to 60 minutes using a volumetric pump
Placebo: Normal saline administered as an intravenous infusion over about 30 to 60 minutes using a volumetric pump</description>
          </group>
          <group group_id="O2">
            <title>Arm B: Placebo Followed by VRC01</title>
            <description>Participants received an infusion of placebo at Day 0 and Week 3 and an infusion of VRC01 at Weeks 6 and 9.
VRC01: 40 mg/kg of VRC01 administered as an intravenous infusion over about 30 to 60 minutes using a volumetric pump
Placebo: Normal saline administered as an intravenous infusion over about 30 to 60 minutes using a volumetric pump</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Levels of Tumor Necrosis Factor Alpha (TNFÎ±)</title>
          <description>Not conducted as part of primary analysis and there are no future plans to assess this outcome. Samples were collected for this outcome in order to assess associations with virologic effects observed. Due to the lack of virologic effect observed, the study team has decided that this outcome is no longer of priority/interest and will be abandoned in favor of saving these samples for future research purposes.</description>
          <population>Analysis not performed. See outcome measure description for reasoning.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Levels of High-sensitivity C-reactive Protein (hsCRP)</title>
        <description>Not conducted as part of primary analysis and there are no future plans to assess this outcome. Samples were collected for this outcome in order to assess associations with virologic effects observed. Due to the lack of virologic effect observed, the study team has decided that this outcome is no longer of priority/interest and will be abandoned in favor of saving these samples for future research purposes.</description>
        <time_frame>Measured at screening, entry and weeks 1, 3, 4, 6, 7, 9, 10, 12, 15, 18 and 30</time_frame>
        <population>Analysis not performed. See outcome measure description for reasoning.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A: VRC01 Followed by Placebo</title>
            <description>Participants received an infusion of VRC01 at Day 0 and Week 3 and an infusion of placebo at Weeks 6 and 9.
VRC01: 40 mg/kg of VRC01 administered as an intravenous infusion over about 30 to 60 minutes using a volumetric pump
Placebo: Normal saline administered as an intravenous infusion over about 30 to 60 minutes using a volumetric pump</description>
          </group>
          <group group_id="O2">
            <title>Arm B: Placebo Followed by VRC01</title>
            <description>Participants received an infusion of placebo at Day 0 and Week 3 and an infusion of VRC01 at Weeks 6 and 9.
VRC01: 40 mg/kg of VRC01 administered as an intravenous infusion over about 30 to 60 minutes using a volumetric pump
Placebo: Normal saline administered as an intravenous infusion over about 30 to 60 minutes using a volumetric pump</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Levels of High-sensitivity C-reactive Protein (hsCRP)</title>
          <description>Not conducted as part of primary analysis and there are no future plans to assess this outcome. Samples were collected for this outcome in order to assess associations with virologic effects observed. Due to the lack of virologic effect observed, the study team has decided that this outcome is no longer of priority/interest and will be abandoned in favor of saving these samples for future research purposes.</description>
          <population>Analysis not performed. See outcome measure description for reasoning.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>VRC01 Antibody Level Relative to Infusion Timing</title>
        <description>Summarize the pharmacokinetics (PK) of two infusions of VRC01 during study follow up - aligning the timing of PK samples/results to the respective VRC01 infusions for each Arm</description>
        <time_frame>Measured immediately after first infusion (and 1, 2, and 3 weeks after), and immediately after second infusion (and 1, 2, 3, 6 and 9 weeks after)</time_frame>
        <population>Analysis of all participants with available results.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A: VRC01 Followed by Placebo</title>
            <description>Participants received an infusion of VRC01 at Day 0 and Week 3 and an infusion of placebo (normal saline) at Weeks 6 and 9.
VRC01: 40 mg/kg of VRC01 administered as an intravenous infusion over about 30 to 60 minutes using a volumetric pump
Placebo: Normal saline administered as an intravenous infusion over about 30 to 60 minutes using a volumetric pump</description>
          </group>
          <group group_id="O2">
            <title>Arm B: Placebo Followed by VRC01</title>
            <description>Participants received an infusion of placebo (normal saline) at Day 0 and Week 3 and an infusion of VRC01 at Weeks 6 and 9.
VRC01: 40 mg/kg of VRC01 administered as an intravenous infusion over about 30 to 60 minutes using a volumetric pump
Placebo: Normal saline administered as an intravenous infusion over about 30 to 60 minutes using a volumetric pump</description>
          </group>
        </group_list>
        <measure>
          <title>VRC01 Antibody Level Relative to Infusion Timing</title>
          <description>Summarize the pharmacokinetics (PK) of two infusions of VRC01 during study follow up - aligning the timing of PK samples/results to the respective VRC01 infusions for each Arm</description>
          <population>Analysis of all participants with available results.</population>
          <units>ug/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>First dose - Post-Infusion</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1726.2" lower_limit="1492.5" upper_limit="1950.3"/>
                    <measurement group_id="O2" value="1643.5" lower_limit="1483.3" upper_limit="2041.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>One week after first infusion</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="259.9" lower_limit="213.0" upper_limit="297.5"/>
                    <measurement group_id="O2" value="277.7" lower_limit="240.7" upper_limit="318.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Two weeks after first infusion</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="147.4" lower_limit="123.3" upper_limit="182.1"/>
                    <measurement group_id="O2" value="158.0" lower_limit="126.6" upper_limit="193.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Three weeks after first infusion</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="113.6" lower_limit="102.2" upper_limit="130.0"/>
                    <measurement group_id="O2" value="98.7" lower_limit="82.8" upper_limit="167.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Second dose - Post-infusion</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1807.7" lower_limit="1617.0" upper_limit="2105.5"/>
                    <measurement group_id="O2" value="1717.8" lower_limit="1446.9" upper_limit="2153.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>One week after second infusion</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="361.9" lower_limit="295.4" upper_limit="432.3"/>
                    <measurement group_id="O2" value="373.8" lower_limit="302.3" upper_limit="416.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Two weeks after second infusion</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="216.9" lower_limit="174.6" upper_limit="254.2"/>
                    <measurement group_id="O2" value="217.2" lower_limit="178.0" upper_limit="301.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Three weeks after second infusion</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="135.8" lower_limit="112.2" upper_limit="164.5"/>
                    <measurement group_id="O2" value="131.1" lower_limit="106.3" upper_limit="215.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Six weeks after second infusion</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.1" lower_limit="21.1" upper_limit="56.8"/>
                    <measurement group_id="O2" value="42.1" lower_limit="30.6" upper_limit="66.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nine weeks after second infusion</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.4" lower_limit="6.3" upper_limit="25.1"/>
                    <measurement group_id="O2" value="18.3" lower_limit="9.0" upper_limit="45.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From first infusion through end of study follow up (the duration of the study is 30 weeks)</time_frame>
      <desc>The SAE Reporting Category, as defined in Version 2.0 of the DAIDS EAE Manual, was used for this study. At entry, signs, symptoms and laboratory values regardless of grade were reported. Post-entry, signs, symptoms and laboratory values grade â‰¥2, or those causing a change in treatment/ART, regardless of grade, were reported. Diagnoses identified on the study-specific list of diagnoses were recorded at entry and at all subsequent visits. Used DAIDS AE Grading Table, Version 2.0, November 2014</desc>
      <group_list>
        <group group_id="E1">
          <title>Arm A: VRC01 Followed by Placebo</title>
          <description>Participants received an infusion of VRC01 at Day 0 and Week 3 and an infusion of placebo at Weeks 6 and 9.
VRC01: 40 mg/kg of VRC01 administered as an intravenous infusion over about 30 to 60 minutes using a volumetric pump Placebo: Normal saline administered as an intravenous infusion over about 30 to 60 minutes using a volumetric pump</description>
        </group>
        <group group_id="E2">
          <title>Arm B: Placebo Followed by VRC01</title>
          <description>Participants received an infusion of placebo at Day 0 and Week 3 and an infusion of VRC01 at Weeks 6 and 9.
VRC01: 40 mg/kg of VRC01 administered as an intravenous infusion over about 30 to 60 minutes using a volumetric pump Placebo: Normal saline administered as an intravenous infusion over about 30 to 60 minutes using a volumetric pump</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 19.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 19.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eye movement disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Anogenital dysplasia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Reactive gastropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Acute sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Bilirubin conjugated abnormal</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Bilirubin conjugated increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Blood alkaline phosphatase abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Blood bilirubin abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Blood creatinine abnormal</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Blood glucose increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Blood potassium decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Blood potassium increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Blood sodium decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Creatinine renal clearance decreased</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Flank pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Muscle twitching</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Burning sensation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Lethargy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Unresponsive to stimuli</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Psychogenic seizure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Genital lesion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Dyspnoea exertional</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Pulmonary sarcoidosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Sinus congestion</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Sinus pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Sneezing</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Fixed drug eruption</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Night sweats</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Pruritus generalised</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Rash papular</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hot flush</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>ACTG Clinicaltrials.gov Coordinator</name_or_title>
      <organization>ACTG Network Coordinating Center, Social and Scientific Systems, Inc.</organization>
      <phone>(301) 628-3313</phone>
      <email>ACTGCT.Gov@s-3.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

